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Abstract 
The therapeutic benefits of cannabis have been known for centuries of years. Yet it has 
only been in the last 40 years that an understanding of the system by which its works in 
our bodies has begun to be defined. This has in turn led to the discovery and 
understanding of the endogenous cannabinoid (eCB) system, alongside its main 
synthesizing and hydrolysing enzymes as well as the endogenous ligands. 
The use of synthetic cannabinoid receptor (CBR) ligands for therapeutic use has provided 
problems regarding the natural endogenous regulatory tone of the eCBs, which in turn 
has resulted in unwanted side effects. Part of the reason of this is due to synthetic 
agonists producing the well documented psychotropic effects at CB t receptors. 
Alternative targets for the manipulation of the eCB system for therapeutic benefits have 
been explored. One remains to be the use of FAAH inhibitors, which in turn potentially 
increase levels of eCBs in the system, hence potentiating their effects at the CBRs, or at 
other receptor sites. Therefore we have developed two HTS assays for the identification 
of potential inhibitors of FAAH and MAGL. They prove to be robust, cheap and facile 
and provide a clear indication of inhibitable levels of FAAH and MAGL activity. The 
FAAH assay can be further used to establish concentration-response curves of initial `hit' 
compounds. Yet, the HTS MAGL assay requires further characterization for use in 
construction of concentration-response curves, as they are not assays specific for MAGL 
acitivity and include hydrolysis of the substrate 4-NPA by non-specific esterases. 
Z-factor scores were calculated for both assays, indicating excellent assays, which can 
potentially be applied to industrial lab robotics for screening of compound libraries. 
The effects of CB hydrolysing enzymes leads to an accumulation of various eCB and 
endocannabinoid-like molecules. One of which is oleoylethanolamine OEA, which has 
shown to have no affinity for CBRs, yet has been documented to have a peripherally 
regulated effect on satiety. This led us to investigate the effects of OEA in feeding 
behaviour and the involvement of the peripherally located nuclear receptor PPARa, in 
wild-type mice and PPARa knockout mice. 
We found OEA to have a transient effect in the reduction of food intake, yet the use of 
genetic tools and PPARa known agonists and antagonists indicated the involvement of an 
additive pathway where OEA also exerts effects of satiety. 
Therefore further investigation is required to fully determine the actions of OEA in vivo 
towards feeding behaviour and to define its therapeutic potential as an anti-obesity 
compound. 
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Introduction 
1.1 Cannabis 
Cannabis, derived from the plant Cannabis sativa L., has a long history of nse as a 
medicine, a material and a psychoactive recreational drug. Cannabis contains over 60 
individual compounds and is arguably one of the most potentially versatile medicines 
available, yet due to the stigma associated with its prohibited legal status, knowledge 
of the pharmacological effects and therapeutic benefits are largely unknown. 
Research into the pharmacological effects of the cannabinoids (CBs) is ever growing 
and their therapeutic effects are beginning to be exploited as medicines. 
Most CBs are extracted from the leaves and mature unseeded female flowers of the 
plant and can be smoked or otherwise orally ingested. 
Today, government controlled sites of plants all cut from a `mother plant', are cloned 
to produce high yields of desired CBs, allowing their extraction and purification and 
separation by gas chromatography mass spectrometry (GC/MS) (Repetto et al., 
1976), for use in medicinal research. 
In 1964, delta-9-tetrahydrocannabinol, or A9-THC, the main psychoactive ingredient 
of cannabis was extracted and isolated by Raphael Mechoulam and his lab (Gaoni Y, 
1964). Experimentally, purified O9-THC has been shown to exert essentially the same 
effects as cannabis preparations. Further investigations lead to the identification of a 
number of structurally related compounds, including cannabidiol (CBD) and 
tetrahydrocannabinovarin (THCV) which are also found in high amounts within 
cannabis but are non-psychoactive (Izzo et al., 2009). 
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Despite its illegal status and registration as a drug of abuse, cannabis still continues to 
be (illegally) used medicinally for the relief of chronic symptoms that are not helped 
by first line treatment drugs. Cannabis is slowly emerging as a potential add-on drug 
aiding drug action in the treatment of various pathological conditions, such as 
reduced spasticity in multiple sclerosis, MS (Baker et al., 2000). 
Medicinal use of cannabis is currently beginning to be licensed around the world, yet 
it still remains a controversial and widely debated drug of use. One of the drawbacks. 
towards cannabis-medicine licensing is the undesirable route of smoking 
administration. Smoking cannabis is, as expected, damaging to your lungs, where 
daily (? ) smoking 3-4 cannabis cigarettes, `spliffs', has been shown to produce 
histological effects on lungs comparable to smoking 20 tobacco cigarettes (Johnson 
et al., 2000). A leading pharmaceutical company in the development of cannabis- 
_ 
based medicines have developed an oromucosal form of delivery allowing production 
and licensing of the only naturally derived cannabinoid (CB) medicine available for 
medicinal use to date, Sativex. Sativex is an equal ratio of THC: CBD, used in the 
treatment of neuropathic pain (Turo et al., 2007), MS (Baker et al., 2000) and is being 
further investigated for its effects in cancer, diabetes and epilepsy. 
In recent decades, funding into the research of cannabis has advanced rapidly, leading 
to the discovery and understanding of CB receptors and their signalling properties. 
This has lead to the identification of an entire endogenous CB system, capable of 
regulating many processes. This chapter continues to describe the receptors, 
hydrolytic enzymes, ligands and signalling of this system and the potential role of 
endogenous CB regulation of feeding behaviour. 
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1.2 Cannabinoid Receptors 
There is evidence of the existence of two types of CB receptor, CB1 and CB2. 
receptors. As well as activation by exogenous CBs, humans are known to produce 
endogenous agonists at the CB receptors, providing both physiological and 
pharmacological importance. The CB 1 receptor was first cloned in 1990 (Matsuda et 
al., 1990) and the CB2 receptor cloned in 1993 (Munro et al., 1993) and have been 
found to be present in many species including human, rat and mouse (Matsuda, 1-997; 
Matsuda et al., 1997). 
The psychotropic effects of cannabis have been known for centuries and their 
measured effects in humans are similar to other drugs known to act via receptor 
mediated mechanisms. These effects are dose-dependant yet stronger than those of 
drugs, such as alcohol (ethanol), which are not thought to be receptor mediated, yet 
cannabinoids are. This and further evidence suggested the CB1 and CB2 receptors 
were members of the superfamily of G protein-coupled receptors (GPCRs). In its 
inactive state, a GPCR co-exists with a G-protein made up as a trimer of Ga, Gß and 
Gy subunits. Guanosine 5'-diphosphate (GDP) is bound to the Ga subunit where 
activation of the receptor induces a number of signal transduction pathways, 
beginning with the displacement of GDP by guanosine 5'-triphosphate (GTP), 
causing the Ga subunit to dissociate from the trimer. GPCRs are coupled to 
secondary messenger systems, such as adenylate cyclase (AC), to which the 
dissociated Ga binds to either inhibit or stimulate the hydrolysis of adenosine 
triphosphate (ATP) to the secondary messenger cyclic adenosine monophosphate 
(cAMP). This is determined by whether the Ga subunit is stimulatory (Gas) of 
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inhibitory (Gai). The receptor returns to its inactive state once guanosine 
triphosphatase (GTPase) activity inherent in the Ga subunit hydrolyses the bound 
GTP to GDP. CBs and the related endogenous ligands are known to evoke signalling 
cascades predominantly through the Gui protein. 
_ 
1.2.1 The CB, Receptor 
Experiments using the radiolabelled synthetic CB compound 3H-CP-55,940 
demonstrated a novel binding site in rat brain (Devane et al., 1988) which led to its 
characterisation as the CB1 receptor. Functional expression of the receptor was 
achieved in Chinese hamster ovary (CHO) cells allowing the demonstration, for the 
first time, that CB1 receptor activation by either O9-THC or CP-55,940 led to the 
inhibition of cAMP production in a concentration-dependent manner (Song and 
Howlett, 1995). Further investigation of the receptor amino acid sequence in cloned 
rat CB 1 receptor, cyclic deoxyribonucleic acid (cDNA) provided confirmation of CB 1 
being a GPCR (Matsuda et al., 1990). 
Sequence analysis of different species clones of the CBI receptor (e. g. mouse and 
human) demonstrated 99% and 97% amino acid identity with rat CB1 receptor 
protein. CB1 receptors have also been cloned in diverse vertebrate species, including 
Taricha granulose (newt) (Soderstrom et al., 2000) and Fugu rubripes (puffer fish) 
(Yamaguchi et al., 1996), displaying 84% and 72% homology, respectively, with 
human CB1 receptors. This high level of species conservation implies a key 
physiological role in animals. 
The distribution of CB1 receptors in the brain is heterogeneous (Glass et al., 1997), 
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and correlate well with evidence for particular pharmacological properties of C$1 
receptor agonists, including the well documented effects of sedation, impaired 
_ 
cognition, motor function and memory, as well as effects on analgesia. 
Animal models, commonly mice, have been developed using disruption of the gene 
encoding the CB1 receptor to create CB1 knockout (CB14) mice. Different methods 
have been used to create CB14" mice, where in the development of the CB14" mouse 
model (Ledent mice), the first 233 amino acids were removed and in the C57B16"1' 
model (Zimmer mice), the entire protein-coding sequence was removed. This appears 
to have differences between CB 1-null mice models in locomotor activity ' and 
nociceptive - responses, which might aid investigations for the actions of the 
endogenous ligands acting on this receptor. Mice lacking the fatty acid amide 
hydrolase gene have also been described, and differences between models may lead 
to identification of agonistic roles of endogenous cannabinoids in various 
physiological functions. 
The CB, Receptor tissue distribution and expression 
CBI receptors appear to mediate most, if not all of the psychoactive effects of A9- 
THC and related compounds. They are predominantly found in the central nervous 
system (CNS) and in some peripheral tissues, including immune cells, heart, lung and 
gastrointestinal tissues. Many of the CB1 receptors are located in the terminals of 
central and peripheral nerves, as they are well known to be pre-synaptic receptors 
involved in the reduction of neurotransmitter release (Pertwee, 2001). They reduce 
the release of various excitatory and inhibitory neurotransmitters in different parts of 
the brain and it is this response which allows the CB1 receptor to modulate pain 
9 
perception (Hohmann and Suplita, 2006), emphasizing the important role of this 
receptor in modulating neurotransmission at specific synapses. The CB 1 receptor is 
dense in the cerebral cortex, as well as being found in the hippocampus, amygdala 
and cerebellum (Mackie, 2005), hence its distribution corresponds well to the most 
prominent behavioral effects of cannabis. In addition, this distribution helps to 
predict potential neurological and psychological routes where manipulation of the 
endocannabinoid (eCB) system might be beneficial. While the knowledge of CB1 
localization in the CNS has advanced much in past two decades, further detailed 
knowledge of the localisation of the precursors for endogenous CBs, the synthesizing 
and hydrolyzing enzymes, specifically in the areas of CB1 receptor distribution may 
allow further development of therapeutic drugs that modify the eCB system. 
CBI receptor clones have been isolated from over 60 different mammalian species, 
which all displayed sequence diversity of 0.41-27% (Stincic and Hyson, 2008). In 
addition to mammals, CB1 receptor has also been isolated from birds (Alonso-Ferrero 
et al., 2006), fish (Soderstrom and Johnson, 2001), amphibians (Soderstrom et al., 
2000) and as has previously mentioned, invertebrates (Beatrice et al., 2006). 
1.2.2 The CB2 Receptor 
The CB2 receptors are mainly expressed in the periphery, and found in immune cells, 
consistent with their anti-inflammatory and immunosuppressive properties (Pertwee, 
1997) (Pertwee, 2001) (Cabral et al., 2001). Investigation of this receptor led to the 
understanding that the CB2, like the CB1, receptor is negatively coupled to AC 
activity via the Gib G-protein (Bayewitch et al., 1995); (Shire et al., 1996). However, 
10 
homology between the two CB receptors is poor, sharing 44% amino acid identity. 
Despite this lack of homology, the eCB and A9-THC have strong binding affinities to 
- 
the CB2 receptor (Mackie and Stella, 2006). Thus, despite their structural differences, 
many cannabinoid compounds have displayed' comparable affinities for both 
receptors (Silvestri et al., 2009). Recent studies indicate that CB2 receptors may 
regulate cytokine release in health and disease (Arevalo-Martin et al., 2008). 
Therefore, it could be hypothesised that, as CB, receptors modulate neurotransmitter 
release, a concerted action of both CB receptors may result in the regulation of the. 
release of neurotransmitters and immune mediators. '- 
The CB2 Receptor tissue distribution and expression 
The CB2 receptor is predominantly found in the immune system, yet recently it was 
reported that there was expression of CB2 receptor messenger ribonucleic 
-äcid_ 
(mRNA) and protein localization on brainstem neurons, the first report of a central 
expression (Van Sickle et al., 2005). Additionally, real-time polymerase chain 
reaction (RT-PCR) methods have located CB2 receptors in the peripheral nervous 
system (Griffin et al., 1997). 
The receptor was initially cloned using a human macrophage cell line HL60 (Munro 
et al., 1993). Since then, it has been reported in many other species, including mouse 
(Shire et al., 1996) (Ho and Zhao, 1996), rat (Brown et al., 2002) and puffer fish 
(Elphick, 2002). Investigation of the distribution of CB2 receptors showed them to be 
specifically localized in immune cells including rat peritoneal mast cells (Carayon et 
al., 1998), mouse splenocytic T-cells (Rao et al., 2004), macrophages (Carlisle et al., 
2002), and a murine T-cell line (Carayon et al., 1998). The rank order of CB2 
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mRNA levels in the periphery has been suggested to be B-cells > natural killer cells 
» monocytes > polymorphonuclear neutrophil cells > T8 cells > T4 cells (Galiegue 
et al., 1995). As GPCRs are known to control cell maturation, proliferation and 
migration, the CB2 receptor distribution suggests it is a good candidate for such 
influences (Cabral et al., 2008). 
CB2 receptor shows less homology between species compared to CB, receptors; for 
example, human and mouse CB2 receptors share 82% amino acid identity (Shire et 
al., 1996) and the mouse and rat CB2 receptor share 93% amino acid identity (Griffin 
et al., 2000). in comparison, human CB1 and CB2 receptors have been shown to share 
68% amino acid homology and only 44% identity through the whole protein (Ban et 
al., 2006) (Pertwee, 1997). 
1.3 The Endogenous Cannabinoid System 
. 
Once the CB receptors were indentified in the 1990s and found to be activated by 09- 
THC (Cravatt and Lichtman, 2003), as well as by its endogenous ligands (e. g. AEA), 
an understanding of the endogenous system began to be established. The endogenous 
cannabinoid (eCB) system comprises of the two receptors, their endogenous ligands 
and the proteins for their synthesis and transformation. Reports of the wider actions 
of both the CBs and the eCB ligands is ever growing, with new activities being 
identified as well as other pathways of transformation 
- 
the understanding of just 
how far the effects of the eCB system extends is yet to be fully defined. This leads to 
further complications in modulating the eCB system in whole animals for different 
therapeutic reasons, as we do not yet understand fully actions of the whole system 
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and therefore of any endogenous effects (compensatory or synergistic) that occur 
when an element of the system is modulated (i. e. 
_ 
alternative eCB synthesis routes or 
hydrolysis enzymes). 
1.3.1 Endocannabinoid Receptor Ligands 
Anandamide (AEA) was the first lipid constituent isolated (from pig brain) shown-to 
activate CB 1 receptors (Devane and Axelrod, 1994) and is an analogue of arachidonic 
acid (Devane and Axelrod, 1994). The identification of 2-arachidonoylglycerol (2- 
AG) as a second eCB strengthened the hypothesis that the G-protein coupled CB 
receptors recognize lipids as their natural ligands (see Figure 1.1) (Cravatt and 
Lichtman, 2003). AEA exhibits similar affinity to the CB1 receptor to that of O9-THC 
and has slightly more affinity to CB1 receptors than CB2, as does 2-AG (Hillard et at., 
1999) (Felder et al., 1995), acting as a partial agonist at both receptors. 
Both AEA And 2-AG belong to two large classes of natural lipids, the fatty acid 
amides (FAAs) and monoacylglycerols (MAGs), respectively. Several FAAs, in 
addition to AEA appear to serve as endogenous signalling lipids. Representatives 
from this group of eCBs are displayed in Figure 1.1 (Cravatt and Lichtman, 2003). 
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Anamdamide 
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Figure 1.1 Chemical structures, and possible molecular targets, of 
representative members of the four classes of fatty acid 
derivatives that are substrates for fatty acid amide hydrolase 
(FAAH) (Cravatt and Lichtman, 2002). 
Despite the structural similarities of these endogenous FAA's, many lack affinity at 
CB receptors, hence are called endocannabinoid-like (eCBL) molecules (e. g. 
Oleoylethanolamide (OEA), palmitoyl ethanolamine (PEA)). A previously 
hypothesised role of the eCBL's is described in section 1.5, yet it is currently 
emerging that these eCBL molecules display affinity for various other families of 
receptors. Despite uncertainty in the physiological roles of many of the eCBL's, these 
other areas of receptor regulation may, in the future, provide additional routes of 
therapeutic interest. Many actions of exogenous and endogenous ligands are 
mediated by the centrally located CB1 receptors. Actions of the eCBs at this 
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receptor have been shown to be blocked by use of the selective CB1 receptor 
antagonist SR141716A, which, up to recently, has been employed clinically as the 
therapeutic compound Rimonabant or Acomplia, used for the treatment of obesity. 
Prolonged use of this agent led to the development of depression and suicidal 
thoughts in patients, resulting in the drug being removed from the market. The 
beneficial and protective role of the eCB system is widely known, hence, the 
outcome of Rimonabant further provided evidence for the necessity and protective 
mechanisms conducted by the eCBs in the CNS via the CB1 receptors. 
1.3.2 Endocannabinoid Synthesis 
eCBs are thought to be primarily synthesised and released at the post-synaptic 
synaptic membrane and act in a retrograde fashion at CB1 receptors located on the 
pre-synaptic membrane, to inhibit or down regulate the release of neurotransmitters 
(see Figure 1.2) (Sipe et al., 2005a). 
AEA has been suggested not to be stored in `resting' cells, but to be synthesised and 
released `on demand' (de novo synthesis) following physiological stimuli, e. g. nerve 
depolarization and the subsequent changes in levels of intracellular calcium (De 
Petrocellis et al., 2004). Depolarisation in post-synaptic neurones opens voltage- 
dependant calcium ion (Ca 2+) channels allowing Ca 2+ to activate the enzyme 
responsible for synthesis of eCBs from their lipid precursors (e. g. N- 
oleoylphosphatidylethanolamine (NAPE)-Phospholipase D for generation of AEA 
from NAPE. Another route of eCB synthesis is through activation of metabotropic 
glutamate (mGlu) receptors, which, in turn, activate phospholipase C (PLC) to make 
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diacylglycerol, which is then broken down by diacylglycerol lipase to form 2-AG. 
1.3.3 Endocannabinoid Signalling 
After their synthesis, eCBs are free to leave the post-synaptic cell and activate pre- 
synaptically located CB1 receptors. As a result of CB1 receptor activation, pre- 
synaptic Ca 2+ influx is inhibited causing a decrease in neurotransmitter release from 
the pre-synaptic neurone (see Figure 1.2). 
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Figure 1.2 Retrograde signalling by endocannabinoids (Sipe et al., 2005a). 
These signalling lipids have been shown to be cell and time specific in their 
production, action and breakdown. 
As previously mentioned in section 1.2.1, identification of the CB receptors as 
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GPCRs negatively coupled to AC, resulting in the inhibition of cAMP production, 
results in various downstream effects. Their involvement in the regulation of many 
pathological states is described later in this chapter. However, this appears not to be 
the only effect produced by these receptors. It has previously been seen in striatum 
tissue, in the presence of both Gild coupled D2 and CBS receptors, that CB receptor 
agonists lead to an accumulation of cAMP through stimulatory G protein (GS) 
activation (Glass and Felder, 1997). Using recombinant cell lines 
- 
this was not 
observed in CB2 receptors (Wade et al., 2004). CB 1 receptors have also been shown 
to inhibit N/P/Q-type Ca 2+ channels, following activation (Begg et al., 2001), as well 
as the activation of inwardly rectifying Potassium (KK) within the CNS (Mackie et al., 
1995) (Felder et al., 1995) (Twitchell et al., 1997). Modulation of Cat' and K+ 
channels primarily affects neuronal signaling resulting in the well known 
neuromodulatory effects of the CB and eCB compounds (Di Marzo et al., 1998). 
Although this effect appears to be mediated solely through CB1 receptors, both CB 
receptors appear to activate mitogen-activated protein kinase (MAPK), following 
GPCR G110-dependant activation (Bouaboula et al., 1997) (Bouaboula et al., 1999). 
MAPK has the ability to phosphorylate other proteins, causing changes in their 
activity and therefore causing further downstream effects into cellular processes. 
1.4 Endocannabinoid Hydrolysing Enzymes 
Any molecule acting as an endogenous regulator of physiological and pathological 
responses requires mechanisms for its action on specific molecular targets and its 
rapid inactivation (De Petrocellis et al., 2004). Following eCB synthesis and CB1 
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receptor activation, the eCB can be taken up pre-synaptically and broken down; 2- 
AG hydrolysis occurs by monoacylglycerol lipase (MAGL)-mediated hydrolysis to 
form AA and glycerol. The mechanism of transport is still to be fully understood. A 
transporter identified on post-synaptic neurones is reported to carry AEA back into 
the neurones, the anandamide membrane transporter (AMT), making AEA available 
to FAAH for hydrolysis into arachidonic acid and ethanolamine (Sipe et al., 2005b). 
The occurrence of this transporter is controversial, however. It is now understood 
that the enzymes lipoxygenase and cyclooxygenase, as well as cytochrome P450s, 
provide alternative routes of transformation of some eCBs, resulting in the 
production of different metabolites, compared to hydrolysis by FAAH or MAGL 
(Pertwee and Ross, 2002). 
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Figure 1.3 Deactivation of endocannabinoids by FAAH in neurons. 
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The characterisation of the principle metabolic pathways of eCB inactivation 
provides an important step towards the understanding and modulation of the eCB 
system. Knowledge of the mechanisms through which the endogenous levels of the 
eCBs, and hence their state of activation at the CB or other receptors, may have a big 
impact on the development of new therapeutic drugs (de Lago et al., 2005). 
1.4.1 Fatty Acid Amide Hydrolase 
As a corollary of the de novo synthesis of endogenous signalling molecules for 
immediate action, eCBs require rapid hydrolysis after their use, so their actions are 
not extended. Hence effective metabolism of eCBs is a prerequisite for their action. 
The principle inactivating (hydrolysing) enzyme of endogenous CB receptor ligands 
is FAAH, which has been identified as the catabolic enzyme inactivating primarily 
AEA (see Figure 1.3) (Sipe et al., 2005b) as well as many other eCBs and eCBL 
compounds; for example, the sleep-inducing eCB oleamide, is broken down into 
oleic acid and ammonia (Fowler et al., 2005). Selective inhibition of FAAH has been 
shown to produce increased levels of AEA, but not 2-AG, in the brain, suggesting 
that MAGL is the main hydrolysing enzyme of 2-AG. 
FAAH Tissue distribution 
FAAH is a dimeric membrane-bound enzyme, found in microsomal and 
mitochondrial membranes, that degrades neuromodulatory fatty acid amides and 
esters. It is an enzyme originally purified and cloned from rat liver microsomes, but 
has also been cloned from three other mammalian species; man, mouse and pig. 
FAAH catalyzes the hydrolysis of both AEA and 2-AG (De Petrocellis et al., 2004) 
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(Bisogno et al., 2002), and is found to be optimally active at alkaline pH. Its 
distribution in the CNS suggests that it is poised to degrade the neuromodulating fatty 
acid amides at their sites of action and is therefore intimately related to the regulation 
of the effects evoked (Boger et al., 2000). 
Often the major hint of the possible physiological role of proteins can be obtained 
from the study of its tissue distribution in mammals. There may be undiscovered 
regions of tissues where FAAH is expressed, as it has sometimes proved difficult to 
detect. For example, little or no activity was initially observed in the gastrointestinal 
tract, due to the presence of endogenous inhibitors of the enzyme, such as the mono- 
acylglycerols, being highly abundant in these tissues (Bisogno et al., 2002). To date, 
high expression of FAAH has been determined in rat liver, brain and testis, with low 
levels in the spleen and very low levels in the heart, as shown in Table 1.1 (Bisogno 
et al., 2002). 
Organs Human Rat Mouse 
Pancreas °°° 
++ 
Brain 000 000 
+++++++++ ++++ 
Kidney 00 00 
Skeletal 
Muscle 
°° ND 
Liver 0 00000 
++++++++++ +++++ 
Placenta 0 
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Heart ND ND ND 
Lung ND ++ ND 
Testis °°° 
++++++ +++ 
Parathyroid °° 
gland +++++ 
Submaxillary °°°° 
gland 
Small °°°°° 
intestine +++ 
Stomach °°°° 
++ 
Spleen °° 
++ + 
Cerebellum 
Esophagus ND 
Colon + 
Table 1.1 Distribution of FAAH activity (+) and mRNA (°, measured by Northern blot) in 
various organs from the rat, mouse and man. ND, not detectable (Bisogno et al., 
2002). 
1.4.2 FAAH activity in vivo 
FAAH's distribution in the CNS suggests that it is poised to degrade 
neuromodulating FAAs at their site of action and is therefore intimately related to the 
regulation of the effects evoked (Cravatt and Lichtman, 2003). 
FAAH inhibitors are not currently in use in any therapeutic areas today. Yet, their 
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potential as a target of eCB system modulation is clearly apparent. 
Different transgenic mice have also been developed lacking the CB, gene. One model 
commonly used for FAAH studies has been developed by Cravatt's lab (Cravatt and 
Lichtman, 2002) (Cravatt et al., 2001) 
, 
where the gene encoding FAAH was 
disrupted by deletion of the promoter region of the gene, producing mice lacking the 
FAAH enzyme (Cravatt and Lichtman, 2002). 
Fatty acid amide hydrolase knockout (FAAH"'") mice were viable, fertile and largely 
indistinguishable from the wild type (FAAH+") litter mates in terms their of general 
cage behaviour, unlike the differences observed with CB1-'- mice (Cravatt and 
Lichtman, 2002). FAAH-'- mice were severely impaired in their ability to degrade 
AEA and responded to normally inactive doses of AEA by producing the typical 
`tetrad' of CB1-dependant behavioural responses which include analgesia, catalepsy, 
hypolocomotion and hypothermia (Bisogno et al., 2002). These behavioural effects 
induced by AEA are reminiscent of those elicited by treatment with the exogenous 
CB A9-THC, suggesting that AEA is indeed acting as an endogenous ligand at CB1 
receptors in vivo (Cravatt et al., 2001). This further supports FAAH as a key regulator 
of AEA signalling in vivo (Cravatt and Lichtman, 2002). AEA's behavioural effects 
in FAAH-'" mice were completely blocked by pre-treatment with the CB receptor 
antagonist rimonabant, hence this model allows further investigation of FAAH 
activity in vivo. 
FAAH distribution in the brain may allow us to correlate its presence with a possible 
involvement in different physiological processes regulated in those areas (see Figure 
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1.2). For example, although discrepancies are seen between the various methods used 
to determine FAAH distribution in the brain; all the cases show the hippocampus to 
have the highest degree of FAAH expression (Bisogno et al., 2002), which is known 
to be involved in the formation of new memories as well as energy balance and 
satiety in mammals. The brainstem and hypothalamus are the areas showing the least 
FAAH expression. Most importantly, FAAH brain regional distribution overlaps to a 
large extent with that of CB 1 receptors, and in some areas where both CB 1 receptors 
and FAAH are expressed, they have complementary distribution, hence areas where 
eCBs act on CB1 receptors are open to CB1 and FAAH manipulation through 
therapeutic agents, depending on eCB function in that area. The low levels of both 
CB, and FAAH in the hypothalamus (the main brain region controlling appetite), 
compared to other brain regions, may suggest eCB involvement in feeding behaviour 
to be occurring through unexpected pathways in the brain than initially anticipated 
(or more peripheral involvement than central), or alternatively, despite the low levels 
of CB 1 receptors in the hypothalamus, tissue or brain area specific manipulation of 
FAAH in different areas of the brain may allow us to further determine the 
involvement of FAAH on feeding behaviour. 
1.4.3 Inhibitors of FAAH 
There have been many different classes of FAAH inhibitors discovered over years in 
CB system research. Fowler has reviewed these classes of inhibitors, non-steroidal 
anti-inflammatorys (NSAIDs): structures of ibuprofen and indomethacin; substrate 
analogues: phenylmethanesulphonylfluoride (PMSF); organophosphates: PMSF; 
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carbamates: URB597) (Fowler et al., 2003) available today. A commonly used 
strategy in the development of enzyme inhibitors is using known substrates as a 
template. This was a method used in the development of OL-135, which is a 
reversible FAAH-selective inhibitor (Lichtman et al., 2004) and belongs to a class of 
a-keto heterocycle inhibitors (Patterson et al., 1996). Further investigation in the use 
of OL-135 found it to promote CB1 receptor mediated analgesia in a number of in 
vivo models of pain (Lichtman et al., 2004). 
A second group of inhibitors are the organophosphates and organosulfates, which 
were in fact accidentally discovered during the characterization of FAAH (Deutsch 
and Chin, 1993) a serine protease inhibitor, PMSF was added to in vitro assay 
samples to prevent degradation of native enzyme preparations and was, in turn, found 
to inhibit AEA hydrolysis. Other inhibitors belonging to this group of compounds 
have been developed, yet they all lack selectivity for FAAH and are therefore limited 
in the potential use as therapeutic modulators of the eCB system (Fowler, 2004). 
The third group of FAAH inhibitors, the carbamates, is the most significant 
developed to date. Until recently, the most potent FAAH inhibitor found in this 
group, URB597, is a reasonably selective FAAH inhibitor, which upon its first 
investigations, was found to increase endogenous AEA levels significantly in rats 
(Kathuria et al., 2003). URB597 is reported to also inhibit other serine hydrolases, 
aside from FAAH, yet the physiological consequences in vivo of this are still 
undetermined (Lichtman et al., 2004). 
The last group of FAAH inhibitors is the group of compounds which exert their 
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primary actions on cyclooxygenase, the NSAIDs. The well known NSAID ibuprofen 
was found to inhibit AEA hydrolyzing activity using rat brain (Fowler et al., 1997), 
as well as indomethacin, which was found to inhibit AEA hydrolyzing activity in 
mouse uterus tissue (Paria et al., 1996). NSAIDs are known to be anti-inflammaotry 
through a mechanism which inhibits prostaglandin (PG) synthesis (Vane, 1971), yet 
their potential action as FAAH inhibitors, which would in turn increase AEA and in 
turn increasing their anti-inflammatory actions through alternative mechanisms 
(involving the eCB system) supports the therapeutic potential of the use of FAAH 
inhibitors. 
1.4.4 Monoacylglycerol Lipase 
As previously mentioned in section 1.4.1, FAAH inhibition, at concentrations that 
block AEA hydrolysis, causes elevation of AEA and not 2-AG (Beltramo and 
Piomelli, 2000). In the case of 2-AG, multiple metabolic pathways are possible, as it 
is also a substrate for lipoxygenases and cyclooxygenases in vitro (Fowler et al., 
2005). Further investigations using FAAH knockout mice reported that hydrolysis of 
a related monoacyl glycerol, 2-oleoylglycerol (2-OG), in brain and liver was 
preserved, while AEA hydrolysis was not (Lichtman et al., 2002) and it was Dinh et 
al in 2002 (Dinh et al., 2002) that suggested 2-acylglycerol (2-AG), but not AEA was 
catalysed by MAGL to convert both 2- and 1- monoacylglycerides to fatty acid and 
glycerol metabolites, further supporting MAGL as the second enzyme of the eCB 
system. 
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1.4.5 Inhibitors of MAGI, 
Until recently there have been no selective inhibitors of MAGL described, but it was 
Cravatt's group developed the compound named JZL-184 (Long et al., 2009), which 
displayed highly selective activity at MAGL to elevate 2-AG levels in brain tissue. 
The testing of several FAAH inhibitors on 2-AG hydrolysing activity using 
membrane preparations, found that, as expected, selective FAAH inhibitors 
(URB597) did not affect 2-AG levels, whereas the non-selective inhibitors (PMSF) 
did (Saario et al., 2004). Yet, now, with the development of JZL184 it is hoped that 
this provide a good template for the discovery of further selective and highly potent 
MAGL inhibitors. 
1.5 The Entourage Effect 
There are several reports that eCBL's, such as OEA and PEA, are potentially 
endogenous substrates for FAAH acting as reversible inhibitors of the primary 
cannabinoid hydrolysing enzyme (Mechoulam et al., 1997). Studies suggest that due 
to the lack of affinity of eCBL's at the CB receptors, their primary role is suggested 
to be to protect AEA from enzymatic hydrolysis by diverting FAAH activity, leading 
to an accumulation and potentiation of eCB effects at the CB receptors, `the 
entourage effect'. The same has been stated for the protection of 2-AG from 
hydrolysis by MAGL by the compounds 2-linoleoylglycerol and 2-palmitoylglycerol 
(Mechoulam et al., 1998). 
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1.6 Therapeutic Potential Of Endocannabinoid Enzyme Inhibitors 
CB receptors and modulators of eCB modulators have various pharmacological 
effects throughout the body and CBs have been used for their therapeutic advantages 
in a wide array of disorders for centuries. CB receptor agonists inhibit the release of 
various excitatory and inhibitory neurotransmitters including glutamate (Shen et al., 
1996), dopamine (Burkey et al., 1997), noradrenaline (Schlicker et al., 1997), and 
acetylcholine (Carta et al., 1998), resulting in acute effects on analgesia, memory and 
reduced locomotor activity. The eCB system itself has been suggested to be involved 
in diseases such as multiple sclerosis (Baker et al., 2001) (Baker et al., 2000), and 
schizophrenia (Leweke et al., 1999). Unfortunately, the unwanted side effects, 
predominantly observed by activation of centrally located CB1 receptors have slowed 
down research into the therapeutic advantages of the eCB system and its ligands and 
also provide a further challenge in using CB1 agonists and, as recent evidence attests, 
CB, receptor antagonists (Tarik Ugura, 2008). This in turn has directed much 
research to turn back towards the effects of peripheral CB 1 receptor activation, 
modulation of the eCB system using the natural partial CB receptor agonists and 
eCBs and looking further into novel peripheral receptor targets and mechanisms 
involving the eCB and eCBL compounds, potentially leading to new therapeutic 
targets. 
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1.7 Endocannabinoids In Feeding Behaviour 
It is well documented that CB agonist induce the onset of feeding, namely `the 
munchies'. This is a central effect, resulting from activation of CB1 receptors located 
directly in the brain (Onaivi et al., 2008). It is known to increase the desire for high- 
calorific foods. 
eCBs in recent years, have been linked with leptin, a gut hormone which plays a key 
part in modulating food intake and body fat. Leptin-deficient mice have been shown 
to become obese and exhibit increased levels of eCBs in the hypothalamus, whereas 
administration of leptin decreases feeding behaviour and consequently shows a 
decrease in levels of AEA and 2-AG in the hypothalamus (Lichtman and Cravatt, 
2005), suggesting a dual role of eCBs in regulating body weight through a central 
orexigenic effect as well as-- a peripheral role in the regulation of lipogenesis 
(Lichtman and Cravatt, 2005). The liver is a primary site responsible for eCB- 
mediated modulation of lipogenesis; hence it links pathways for peripheral 
lipogenesis and central appetite regulation by an eCB signalling system, primarily in 
the hypothalamus (Lichtman and Cravatt, 2005). The eCB system in the liver 
undergoes adaptive changes in response to diet, mice maintained on a high-fat diet 
developed fatty liver associated with increases in hepatic expression of CB1 and 
increased levels of AEA (Lichtman and Cravatt, 2005). This increase in hepatic AEA 
appears to be a result of decreased FAAH activity, although the level of FAAH 
activity was unaffected directly by diet. It was suggested that this phenomenon was 
mediated through elevation of FAAs, like the eCBL's and other endogenous factors, 
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competing for FAAH hydrolysis (Lichtman and Cravatt, 2005). 
CB 1 activation of hepatic cells leads to an increase in hepatic fatty acid synthesis by 
increasing the expression of lipogenic transcription factor sterol response element- 
binding protein-lc (SREBP-1c). SREBPlc regulates the expression of genes 
involved in fatty acid synthesis, including acetyl coenzyme carboxylase-1 and fatty 
acid synthase. Treatment of mice with a potent CB1 agonist (HU-210) increases free 
fatty acid (FFA) synthesis by increasing hepatic levels of SREBPIc and its regulated 
genes, and this has been shown to be prevented by pretreatment with rimonabant 
(Lichtman and Cravatt, 2005). 
This mechanism provided a target for anti-obesity treatment, leading to the 
production of rimonabant. In animal studies, rimonabant was found to mediate 
hypophagia through reduction of the appetitive or preparatory aspects of the 
motivation to feed, as well as causing reduced food consumption behaviour through 
the inhibition of the positive feedback processes which are normally associated with 
food intake (Thornton-Jones et al., 2005). But its lack of success as a therapeutic drug 
was due to inhibiting the actions of many eCBs at CB1 receptor, which clearly 
regulate the beneficial effects of eCB's on regulating mood. Hence, new mechanisms 
for the effects of eCB's and the eCBL's on non-CB receptors and other receptor 
groups are being researched. 
Obesity has also been found to be associated with a dysregulation of eCBs, where 
animal models of genetically-induced obesity show long-lasting overstimulation of 
the eCB system synthesis, leading to a permanent activation of the CB, receptor, 
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which may, in fact, help maintain their obese state (Pagotto et al., 2005). Studies have 
also shown the up-regulation of CB1 receptor in obese animals, further supporting a 
role for the CB1 receptor in obesity. This group also found that peripheral CB1 
receptor activation stimulates lipogenesis in adipocyte cells and CBS receptor 
antagonists demonstrate increased adiponectin production in 
_adipocyte cells. 
Adiponectin drives fatty acid oxidation and free FFA clearance. Such findings favour 
a peripheral CB1 receptor target as an alternative route of eCB modulation for the 
treatment of obesity. 
1.7.1 OEA and Peripheral Regulation of Feeding 
Clearly FAAH regulates the levels of several endogenous FAAs, most 
_of which do 
not interact with CB receptors, but appear to possess distinct sites of action and 
functions in the nervous system and periphery. The functions of many of these 
`orphan' FAAs and how these activities might be affected by FAAH inhibition is an 
area of research with possible leads to therapeutic benefits. We know that symptoms 
of several central and peripheral disorders are due to, or are related to, changes in 
eCB biosynthetic and degradative pathways, and, subsequently, of pathologically 
altered activation of either CB1 or CB2 cannabinoid receptors, or alternatively 
differing peripheral receptor activation (de Lago et al., 2005). If it is found that the 
symptoms of a certain disorder are caused, for example, by altered eCB levels or that 
eCBs are produced in order to counteract the symptoms or the progress of the 
disorder, then substances selectively inhibiting eCB hydrolysis may produce 
beneficial effects by prolonging eCB life-span and enhancing eCB levels (de Lago et 
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al., 2005). 
Studies of peripheral regulation of feeding and appetite have identified that OEA is 
produced in the small intestine in response to food. It is suggested to activate nerves 
in the walls of the small intestine, rather than in the brain, to send a signal to parts of 
the brain (hypothalamus and nucleus accumbens) which control food intake, and so 
to reduce appetite directly at the satiety centre. 
It was hypothesized whether OEA worked in the same manner as gut hormones, 
being carried in the blood to directly activate their receptors in the brain (e. g. ghrelin, 
Cholecystokinin (CCK), glucagon-like peptide-1 (GLP-1) to regulate feeding. 
Studies have, however, shown OEA not to cause changes in circulating gut hormone 
levels (Proulx et al., 2005). Alongside this, Cravatt's group (Rodriguez de Fonseca et 
al., 2001) showed that OEA injected directly into the brain, in mice, did not exert 
orexigenic effects, yet it did when injected i. p., further indicating OEA to be involved 
in a peripheral receptor mechanism regulating food intake. 
The actions of OEA have been investigated primarily in the GI tract. It was 
Piomelli's group in 2006 that found onset of feeding led to mobilisation of OEA in 
proximal areas of the small intestine (duodenum) and alongside this, the OEA- 
generating precursors N-acyl phosphatidylethanolamine (NAPE) and expression of 
its synthesizing enzyme N-acyl phosphatidylethanolamine phospholipase D (NAPE- 
PLD) was increased. FAAH activity decreased along with these changes upon 
feeding, indicating nutrient availability to regulate and control this peripheral effect 
of feeding (Piomelli et al., 2006). So it can be wondered whether ingested foods 
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transit through the small intestine and stimulate nutrient-sensing cells, causing the 
release of bioactive peptides and lipid mediators (such as OEA) or increase the 
activity of NAPE-PLD, eventually leading to the OEA mediated effects. So, it is 
possible food intake may also control the mobilization of OEA and act as a lipid 
derived satiety factor, yet the molecular mechanisms underlying OEA release in the 
gastro-intestinal (GI) tract are still undefined. 
OEA resembles the endogenous lipids that activate the peroxisome proliferator- 
activated a receptor (PPARa) family of nuclear receptors. These receptors are the 
target of fibrate drugs used in the treatment of hyperlipidemia (Lo Verme et al., 
2005). OEA has been found to have high binding affinity to PPARa, with in vitro 
analysis displaying maximal effective concentration (EC50) values of 120 nanomolar 
(nM). Such a low activation concentrations suggests levels of OEA in the gut, in 
response to feeding, are adequate enough to cause full activation of PPARa, as well 
as this OEA is found to be present in the same areas as PPARa (Fu et al., 2003), 
further indicating its importance in food regulation. 
Activation of PPARa by OEA seems sturucturally selective, as other eCBL's 
(stearoylethanolamide; SEA) and eCB's (AEA) do not show any effect at this 
receptor (Stella and Piomelli, 2001). Interestingly, the range of fibrate drugs used to 
induce antihyperlipidemc effects are actually weak PPARa agonists and demonstrate 
in vivo to have no anorexic effects (Fu et al., 2003). 
Direct injection of OEA into the brain failed to evoke a reduction in appetite, while 
PPARa null (PPARa 4-) mice were still responsive to OEA (Rodriguez de Fonseca et 
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al., 2001). OEA effects at PPARa receptor suggests a potential therapeutic route 
toward obesity treatment, possibly through tissue specific modulation of FAAH 
activity creating an accumulation of OEA in areas of the GI tract, which may have 
benefits on appetite reduction and lipid lowering, as well as powerful insulin- 
sensitising agents. 
The regulation by feeding of OEA levels in the duodenum and jejunum (Rodriguez 
de Fonseca et al., 2001) (Fu et al., 2003) implies that OEA may act on PPARa 
receptors localized within cells of the small intestine. It has been reported that OEA 
content in rat small intestine rises from 132 ± 18 picomolar per gram (pmol/g) in a 
fasting state to 329 ± 150 pmol/g after feeding (Rodriguez de Fonseca et al., 2001), 
where the concentration of OEA found post-feeding is two-fold higher than the EC50 
of OEA for PPARa (120 nM), suggesting that post-feeding levels of endogenous 
OEA are high enough for PPARa receptor activation (Fu et al., 2003). 
It has been hypothesized that OEA exerts its effects on peripherally located receptors 
leading to signals sent via vagal sensory neurons located in the walls of the small 
intestine, directly to the hypothalamus to induce satiety (Fu et at., 2003) (Rodriguez 
de Fonseca et al., 2001), yet the mechanism by which OEA exerts this effects is still 
undetermined. The chain of molecular events that join PPARa activation to vagal 
sensory fibre recruitment is unknown, but it has been hypothesized that the message 
between the receptor and neuron may, at least in part, be through the release of nitric 
oxide (NO). It has been reported that enterocytes produce large amounts of NO and it 
may have a role as a peripheral appetite-stimulating signal (Calignano et al., 1993). 
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We know PPARa represses the expression of inducible NO synthase (iNOS), which 
is responsible for the production of NO (Fu et al., 2003) (Gaetani et al., 2003)], 
therefore through the repression of iNOS by PPARa may well contribute to the 
effects of OEA on satiety. These studies have also shown that OEAs actions are rapid 
and transient (Gaetani et al., 2003), which contrasts with traditional mechanisms of 
PPARa activity, associated with gene transcriptional changes. OEAs effects on 
PPARa may, therefore, provide evidence for the involvement of PPARa receptors in 
-non-transcriptional mechanisms. 
1.7.2 GPR119 
A recently deorphanised GPCR, GPR119, was suggested to be a close relative of the 
CB receptors on the basis of amino acid sequence comparisons (Overton et al., 2006). 
Tissue distribution of GPR119 is still incompletely defined, yet transcripts of human 
and rodent GPR1 19 have been found predominantly in intestinal tissues and the 
pancreas (Lauffer et al., 2008) (Soga et al., 2005) and rodents have also been found to 
express the receptor in certain brain regions (Overton et al., 2008). Using 
immunoreactivity methods, GPRI 19 was found to be localized in the villi in small 
intestine (Chu et al., 2007). Its has been reported that cells expressing GPR119 at 
concentrated levels display a constitutive increase in cAMP (Chu et al., 2007), which 
implies GPR119 to be coupled to a stimulatory G protein (G, ). Due to the high level 
of homology between GPR119 and the CB receptors, compounds active in the eCR 
system were first investigated for their actions on GRP 119. It was found that OEA 
showed the highest affinity to GPRI 19, followed by PEA and SEA, which displayed 
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weak effects at the receptor, with AEA apparently inactive (Overton et al., 2006). 
OEA stimulated cAMP production in cell lines expressing GPR 119, where cells 
without GPR119 failed to produce an effect. As previously mentioned, OEA 
produces hypophagia apparently through activation of PPARa (Fu et al., 2003) 
(Rodriguez de Fonseca et al., 2001). Like OEA, a synthetic GPR119 agonist 
suppressed food intake and weight gain in vivo, but displayed no effect at the PPARa 
receptors. Interestingly, OEA displayed equipotent effects in the suppression of food 
intake in wild-type and GPR1 19 deficient mice (Lan et al., 2009), which suggests 
that these GPR119 agonists may work through different mechanisms, or obtain 
additive effects aside from activity at GPR119. OEA at a dose of 30 milligrams per 
kilogram (mg/kg), administered i. p., displayed a significant reduction in food intake 
in free feeding rats, and this effect was shown to last up to 2 hours post-injection, 
indicating a transient effect at this receptor (Overton et al., 2006). The agonist action 
of OEA on GPR119, leading to a reduction in appetite, provides a clear therapeutic 
target for the development of GPR119 agonists for the regulation of appetite and 
feeding behavior in vivo. 
1.7.3 rRPV1 
TRPV 1 is expressed in both nociceptive neurons, where it is involved in the detection 
of noxious chemicals and thermal stimuli, and in visceral sensory neurons and brain, 
where it could have a role in food intake control. OEA has been shown to have 
affinity for and directly activate TRPV1 receptors with an EC50 of -2 micromolar 
(pM) at room temperature (Ahern, 2003). This effect was seen to be through direct 
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phosphorylation of TRPV 1, as no responses to OEA were observed with TRPV 1 
receptors lacking critical PKC phosphorylation sites. Hence, if TRPV 1 is 
phosphorylated by the protein kinase C (PKC), it becomes more sensitive to OEA 
activation and therefore it is thought to work in a PKC-dependent manner, resulting 
in OEA-induced Ca2+ rises that were selective for capsaicin-sensitive cells, in sensory 
neurons. This effect was inhibited by the TRPV 1 antagonist, capsazepine. This 
provides evidence that TRPV1 represents a potential target for OEA and may 
contribute to the excitatory satiety signalling action of OEA, where TRPV 1 provides 
access for OEA stimulation of the vagal sensory nerve to signal satiety directly to the 
hypothalamus. 
It has also been found that some effects of OEA mediated by TRPV1 receptor may be 
a result of OEA acting as an antagonist. It has been hypothesised that, in addition to 
the actions of OEA at PPARa receptors to cause modulation of food intake and lipid 
metabolism, circulating OEA could block TRPV 1 receptors on neuronal cells. This 
mechanism would modify the electrical status of the Ca2+ channel, inducing small 
depolarization (Wang et al., 2005). Therefore, the vagal sensory nerves would be 
excited, directly influencing food intake regulation. To confirm TRPV 1 involvement 
in OEA effects on food intake, normal mice and TRPV1-null mice were injected with 
OEA (12.5 mg/kg). Short-term feeding was significantly reduced in the control 
group, but not in the TRPV1-null group, showing the role of this receptor in feeding 
regulation (Movahed et al., 2005) (Wang et al., 2005), providing further evidence of 
another possible peripheral route for the hypophagic actions of OEA in vivo. 
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1.7.4 Peroxisome Proliferator-Activated Receptor-alpha (PPARa) 
Peroxisome proliferator-activated receptors (PPARs) are a group of nuclear receptors 
that function as transcription factors and regulate the expression of genes (Michalik et 
al,. 2006), leading to the regulation of metabolism. There are three types of PPAR 
subtypes which have been identified and named alpha (a), gamma (y), and delta (S) 
(beta) (Berger et al,. 2002). PPARs are found to be in most cells in the body, high 
levels of expression of PPARa are found in the liver, heart, muscle and adipose 
tissue. PPARJ/S are also found predominantly in adipose tissue as well as the brain 
and PPAR y has three isoforms which are found in almost all tissues of the body. 
The function of PPARa is dependent on the binding properties of its ligand and as 
well as having synthetic agonists, like fenofibrate, it is also activated by endogenous 
ligands such as free fatty acids and has now led to investigate the ligand binding 
effects of endogenous cannabinoid ligand OEA. Research into the role of PPARa 
agonist by the endocannbinoid OEA has indicated a possible site of peripheral 
regulation of food intake. PPARa is the main target of fibrate drugs, a class of 
amphipathic carboxylic acids medications currently on the market (clofibrate, 
gemfibrozil, ciprofibrate, bezafibrate, and fenofibrate) for the treatment of disorders 
creating high levels of both cholesterols and triglycerides. 
Fenofibrate 
Fenofibrate is a fibric acid and is a well-established PPARa agonist displaying lipid 
modifying effects in humans, with all effects mediated by activation of PPARa. The 
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agonist action of fenofibrate, like other fibrates, produces dyslipidaemic effects by a 
reduction in low density lipoproteins (LDL) and very low density lipoproteins 
(VLDL) alongside an increase in high density lipoproteins (HDL) and a reduction in 
triglyceride levels. In addition, through modulation of the synthesis and catabolism of 
VLDL fractions, fenofibrate increases the LDL clearance and reduces small and 
dense LDL, the levels of which are found to be elevated in coronary heart disease 
(Yang et al,. 2009) as well as a beneficial effect in insulin resistance (Wysocki et al,. 
2004). Fenofibrate has also been used as an add-on therapy to the use of statins as it 
increases the serum level of statins, therefore, a lower dose of statin is generally 
necessary in the treatment of hypercholesterolemia and hypertriglyceridemia. 
PPARa antagonist GW6471 
GW6471 is a PPARa antagonist, yet very little is known of GW6471 pharmacology. 
It has mainly been used in vitro to investigate interruption of PPARa binding and 
transcriptional activity. GW6471 has only been reported once to being used in vivo, 
using an intraplantar injection as route of administration, not allowing for the 
observation of potential behavioral effects caused by systemic circulation in vivo. The 
understood rationale of PPARa antagonism does not lead to the need of its 
investigation. Chronic activation of PPARa would lead to a metabolic shift leading to 
the utilisation of proteins as an energy source and extensive degradation of proteins 
can lead to myopathy or rhabdomyolysis (Motojima, 2002). Hence the development 
of a specific PPARa antagonist and research in this area is limited to date. In this 
instance, new knowledge of the involvement of the cannabinoid system, in particular 
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OEA, and its actions and potential effects regulated by PPARa provides GW6471 as 
a tool for the investigation of mechanism pathways involved in the effects of OEA. 
Yet results of its use as a pharmacological tool may be limited as its absorption 
profile in vivo is unknown and therefore effective dosing remains an issue. 
1.8 Aims and objectives 
The aims of this thesis is to develop functional high throughput screening (HTS) 
assays, which are rapid, cheap and facile, for the identification of potential inhibitors 
of both the main eCB system hydrolysing enzymes FAAH and MAGL leading to 
potential eCB system modulation. Where inhibition of these enzymes would lead to 
an increase in the endogenous tone of eCBs and eCBL molecules, we have 
investigated the role of eCBL compound OEA, its peripheral role in the regulation of 
feeding and satiety signaling and whether its response is mediated by PPARa 
receptors in the periphery. This would therefore provide further information towards 
targeting FAAH with inhibitors and whether this may be a potential therapeutic target 
for the beneficial increase of OEA towards regulation of feeding behaviours. 
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Chapter 2: Characterisation of a novel assay for fatty 
acid amide hydrolase activity 
2.1 Introduction 
2.1.1.1 Existing assays for Fatty Acid Amide Hydrolase activity 
In recent years, there has been increased interest in the potential therapeutic benefits 
of FAAH inhibition, which has stimulated research into FAAH activity assay 
development for novel inhibitor identification. The predominant methods of FAAH 
assay involve radiochemical and chromatography methods. Radiochemical methods 
involve incubation of FAAH with a radiolabelled substrate; separation of the 
radioactive reaction product then allows determination of the FAAH reaction rate. 
Chromatography methods applied include mini-column chromatography (Desarnaud 
et al., 1995), thin layer chromatography (Deutsch and Chin, 1993), or reverse-phase 
high performance liquid chromatography (Marcelis van der et al., 1997) (Maccarrone 
et al., 1999). An alternative to radiochromatography methods involves the use of 
anandamide (or related substances) radiolabelled on the ethanolamine section of the 
compound, allowing measurement of the radioactive cleaved portion of the substrate 
following FAAH catabolism. An organic solvent is used to stop enzyme activity, at 
the same time generating two phases, where the ethanolamine hydrolysis product 
partitions into the aqueous phase, leaving unreacted substrate to remain in the organic 
phase. The aqueous phase is sampled for activity measurement using scintillation 
counting, eliminating the use of chromatography (Omeir et al., 1995), essentially, 
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making it the `gold standard' for FAAH/assay activity. 
Other assays have described the use of non-radioisotopic chromatography methods to 
determine FAAH activity. One version employed UV absorbance detection (at 204 
nm) following separation of arachidonic acid from FAAH substrates by HPLC, 
which involves extraction of reaction products containing carbon-carbon double 
bonds, following substrate-enzyme incubation, which are then identified by RP- 
HPLC as a measure of FAAH activity (Lang et al., 1996). A follow-up assay from 
the same group used o-phthaldehyde derivatization of the evolved ethanolamine 
following FAAH-catalysed anandamide hydrolysis, which involves anandamide 
incubation with FAAH, followed by addition of o-phthaldehyde which separates the 
reaction product ethanolamide, by binding to it, producing an isoindole derivative, 
with subsequent HPLC separation and detection at 230 nm (Qin et al., 1998). 
Despite their high levels of sensitivity (femtomolar range) for FAAH activity, all of 
these methods have limitations in their use, by being either expensive due to the use 
of radiolabelled substrates, time-consuming because of the chromatographic analysis, 
or both. 
Two further methods of FAAH assay appeared to reduce some of the drawbacks 
mentioned above. One method used oleamide as a FAAH substrate, measuring the 
reaction product ammonia using ion-specific electrodes (Patterson et al., 1996). A 
second assay, based on fluorescence ligand displacement, measured arachidonic acid 
or oleic acid production from anandamide or oleamide hydrolysis, since the fatty 
acids compete for binding of a fluorescent fatty acid analogue, DAUDA (11-(5- 
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dimethylamino napthalensulphonoyl)-undecanoic acid), to a fatty acid binding 
protein (Thumser et al., 1998). However, these methods still have drawbacks. The 
first method requires large assay volumes (10 mL) to accommodate the size of the 
electrode. The second assay involves the laborious extraction of the binding protein 
from rat liver or E. coli expressing the recombinant protein. Also, there was 
significant cross-sensitivity to the substrates anandamide and oleamide, reducing the 
usefulness of the assay. 
FAAH assays using fluorogenic reaction products are attractive for the development 
of high throughput screening (HTS) methodologies. One such method involved the 
use of AAMCA (N-arachidonoylaminomethylcoumarin) as a novel FAAH substrate 
(Ramarao et al., 2005). The fluorescent product 2-amino-7-methylcoumarin was 
measured in a kinetic manner over 1 hour, limiting screening time. 
A further development in FAAH activity assays from the labs in Nottingham was the 
use of a spectrophotometric dual-enzyme assay to measure the rate of ammonia 
production from oleamide hydrolysis (De Bank et al., 2005) L-Glutamate 
dehydrogenase catalyses the production of glutamate from the ammonia product and 
2-oxoglutarate, using NADH as a co-factor. The oxidation of NADH to NAD+ can be 
measured using a UV spectrophotometer due to its high molar extinction coefficient 
at 340 nm. The reduction in absorbance is directly proportional to the hydrolysis rate 
of oleamide. Although this assay was amenable to HTS screening, it has the 
drawbacks of being an indirect assay of FAAH activity, as well as being a 
`destructive' assay, where a decline in the parameter measured reflects enzyme 
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activity. A more useful method measures accumulation of a product to allow viable 
measurement of low enzyme activities. 
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2.2 Objectives 
Due to the limitations of these existing assays, we aimed to develop a simpler end- 
H2S03 
point FAAH assay, which would be rapid, cheap and sensitive, as well as being 
amenable for high throughput screening (HTS). We continued to use oleamide as a 
FAAH substrate, where oleic acid and ammonia are the resulting reaction products 
(DeBank et al., 2005), to develop a simple two-step assay. We used the novel 
approach of derivatising the reaction product ammonia with o-phthaldehyde in the 
presence of (hydro) sulphite to generate a I-sulphonatoisoindole fluorescent 
derivative at alkaline pH (Scheme 2.1). Fluorescence can then be detected at 
wavelengths of ex. 360, em. 490 nm and directly indicates the rate of ý oleamide 
hydrolysis by FAAH. 
NH2 OH 
oleamide Oleic acid 
NH3 
i 
Iý 
OPA 
ý 
o_ 
, S, o 
NH 
I 1-sulphonatoisoindole 
Scheme 2.1 Reaction mechanism of FAAH-catalysed oleamide hydrolysis with reactant 
product ammonia's reaction with o-phthalaldehyde (5 mM) and sulphite (5 
mM) to produce the highly fluorescent 1-sulphonatoisoindole derivative. 
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2.3 Materials and Methods 
2.2.1 FAAH assay development 
There are many individual factors which can cause variation in assays. This chapter 
identifies a number of such factors allowing optimisation of an assay which can relate 
measured fluorescence to specific enzyme-substrate activity. 
2.2.2 Preliminary optimisation 
In preliminary experiments to identify assay parameters, assay volumes of 500 µL or 
greater were employed with a view to later scaling down the volumes for microtitre 
plate usage. 
Tissue preparation 
Fresh rat liver, which expresses high FAAH activity (Giang and Cravatt, 1996), was 
cut into pieces, hand homogenised in 1: 10 weight/volume (w/v) phosphate (P04) 
buffer (0.2M, pH 7.4) on ice and centrifuged for 15 minutes at 1000 g and 4°C. The 
pellet was discarded and supernatant layer centrifuged for 30 minutes at 30000g and 
4°C. The supernatant, cytosolic fraction was discarded and the pellet, membrane 
fraction was re-suspended 1: 1 in P04 buffer and stored in 1.5 mL Eppendorf tubes at 
-80°C until required. 
FAAH preliminary assay method 
FAAH substrates were prepared as 10 mM stock solutions in 100% dimethyl 
sulfoxide (DMSO). A reaction mix was made up with 90% 0.2M P04 buffer, 10% 
Magnesium Sulphate (MgSO4) (5 mM), 1% triton X-100 (TX-100) (0.01 %), 1% 
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membrane fraction. I mL reaction mix was then incubated with 10 µL inhibitor 
(URB597, final concentration 5 MM) or DMSO and 10 µL endocannabinoid substrate 
(100 µM) in 4 mL polystyrene tubes. These components were incubated for 30 
minutes at 37°C, before termination of the reaction by the addition of 0.5 mL 5% 
trichloroacetic acid (TCA), followed by centrifugation for 5 min at 5000 g. A 
developing buffer was made up using 5 mM o-phthalaldehyde (OPA) dissolved in 0.5 
mL ethanol, 5 mM hydrosulphite and 20 mL 0.4 M potassium phosphate buffer, pH 
11.4.80 µL aliquots of the incubation mix were added to 160 }tL OPA solution and 
then incubated for 30 minutes at room temperature, after which the samples were 
read at wavelengths of exitation (ex. ) 360 emission (em. ) 490 nm. Enzyme blanks 
were run alongside the test conditions, as well as standards using 100 pM ammonium 
sulphate to allow quantification of evolved ammonia. 
2.4 Results 
2.4.1 Substrate specificity 
FAAH is a membrane bound enzyme which hydrolyses a number of primary and 
secondary fatty acid amides. The structurally related compounds erucamide (docosa- 
13,14Z-enamide), stearamide (octadecanamide), elaidamide (octadec-9,10E-enamide) 
and oleamide (octadec-9, l OZ-enamide) were employed as substrates over a range of 
concentrations (Figure 2.1). 
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Figure 2.1 FAAH activity using ECL's as substrates 
Activity of rat liver preparations against four primary amides in a 
fluorescence-based FAAH assay. The data are mean ± Standard 
error of mean (SEM) from six preparations, with four individual 
replicates; curves were fitted to rectangular hyperbolae using 
GraphPad Prism. 
Of the four substrates investigated, oleamide appeared to be the `best', with 
stearamide and elaidamide showing lower activity and erucamide exhibiting almost 
no hydrolysis (Figure 2.1). These results, although limited in nature, highlight the 
influence of fatty acid chain length and the presence & orientation of the unsaturation 
on FAAH activity. Although a comparing the activities of oleamide and erucamide 
indicates that increasing the chain length from 18 carbons to 22 carbons greatly 
reduces enzymatic hydrolysis. Although kinetic parameters for oleamide as a FAAH 
substrate were measurable, it was only possible to estimate erucamide hydrolysis at 
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100 µM (Table 2.1). Similarly, changing the orientation of the unsaturation 
(oleamide vs. elaidamide) reduced enzymatic hydrolysis, as did saturation of the 
double bond (oleamide vs. stearamide) (Table 2.1). 
Rate of hydrolysis at 100 
Substrate K. Vm. (nmoles/min/mg µM (µM) protein) (nmoles/min/mg protein) 
Oleamide 77 5.9 3.37 ± 0.54 
Elaidamide 170 3.9 1.42 ± 0.73 
Stearamide 48 2.0 1.36 ± 0.79 
Erucamide NC NC 0.37 ± 0.26 
Table 2.1 V and K. values for four FAAH substrates calculated from the 
FAAH assay (n=6). NC 
- 
not calculable 
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2.4.2. Incubation Time 
The longer an enzyme is incubated with its substrate the greater the amount of 
product formed, at the same time, however, enzyme denaturation and product 
inhibition can lead to a loss of catalytic activity. Enzyme activity was, therefore, 
investigated up to 60 minutes with a range of oleamide concentrations (Figure 2.2). 
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Figure 2.2 Effect of incubation time on FAAH-oleamide hydrolysis using 
solubilised rat liver membrane fraction with varied concentrations 
of oleamide. The data represent mean t SEM values obtained 
from four tissue preparation, with four individual replicates. 
Results of varied incubation times on FAAH activity can be seen in figure 2.2. Rates 
of hydrolysis are dependant of time and oleamide concentration. Higher 
concentrations of oleamide (100 µM) show a more linear response in hydrolysis with 
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an increase in time. 
For later screening of potential inhibitors, a time point of 30 minutes was chosen as a 
compromise between rapidity of assay and accumulation of product. 
2.4.3 The influence of plastics on substrate preparation 
Since fatty acids and their derivatives are capable of adhering to plastics, a 
comparison was made of preparing 10 mM oleamide stocks in DMSO in either 
Eppendorf (polycarbonate polypropylene) or LP4 (polycarbonate polystyrene) tubes 
(Figure 2.3). 
-u - LP4 *** 4+ Eppendorfs 
E 
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Figure 2.3 Effects of preparation materials on sample preparation in 
polycarbonate polypropylene Eppendorf or polycarbonate 
polystyrene LP4 tubes. 10 mM oleamide stocks were diluted in 
glass vials and assessed for FAAH-catalysed hydrolysis, using 
solubilised rat liver membrane fractions. Data are expressed as 
the mean ± SEM of triplicate values obtained from three 
independent experiments and were analysed by two-way ANOVA 
with Bonferroni post-hoc test (***P<0.001). 
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Given the apparently higher level of FAAH activity with substrate prepared in LP4 
tubes compared with Eppendorf tubes (at least at the highest concentration), it 
appears that the polycarbonate polypropylene plastics retain some of the oleamide 
(Figure 2.3) and so these were avoided in future substrate preparation. 
2.4.5 The influence of DMSO on the FAAH assay 
Dimethylsulfoxide (DMSO) is a widely used solvent able to dissolve both polar and 
non-polar compounds, with good miscibility in a wide range of aqueous and organic 
solvents, making it popular for drug dissolution in biochemistry/pharmacology. 
Preliminary investigations suggested that oleamide was soluble in 1% DMSO up to 
100 µM, while concentrations above 100 pM required higher DMSO concentrations. 
The influence on the FAAH assay of concentrations of DMSO up to 10% were, 
therefore, compared with similar concentrations of ethanol using two concentrations 
of oleamide. 
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Figure 2.4 The effect of the presence of increasing solvent concentrations of 
0-10% DMSO/EtOH on the FAAH-catalysed hydrolysis of 50 µM 
and 100 pM oleamide in solubilised rat liver. Data, conducted in 
triplicates, are expressed as the mean ± SEM from three 
independent experiments. 
It appeared that the presence of either solvent up to 10 % was well tolerated in the 
FAAH assay (Figure 2.4). However, the increased variability of activity observed 
with ethanol suggested DMSO was a better solvent for later investigations. 
2.4.6 The influence of Bovine serum albumin (BSA) on FAAH activity 
Bovine serum albumin appears to stabilise many enzyme activities by acting as a 
weak anti-oxidant as well as preventing adhesion of enzymes to reaction material 
surfaces. Additionally, albumin has been found to bind reversibly a wide variety of 
ligands, and is described as the principle carrier of fatty acids that would otherwise be 
insoluble in circulating plasma (Spector et al., 1978), including the endocannabinoids 
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(De Petrocellis et al., 2001; Ross et al., 2001; Parolaro et al., 2002; Hillard et al., 
2003). The effects of BSA on FAAH activity in the fluorescence-based assay were, 
therefore, investigated. 
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Figure 2.5 The effects of pre-incubation with varied concentrations of BSA 
during FAAH-catalysed hydrolysis of 100 pM oleamide using rat 
liver microsomal preparations. Data, conducted in triplicates, are 
expressed as the mean f SEM from four individual experiments 
analysed using two-way ANOVA with Bonferroni post-hoc test, 
compared with the absence of OEA 
(* P<0.05, ** P<0.01, *** P<0.001). 
BSA increased apparent FAAH activity in a concentration-dependent manner 
(Figure 2.5). It is possible that BSA enhances the `presentation' of oleamide to the 
enzyme, or alternatively, binds the oleate product reducing the possibility of product 
inhibition. The BSA concentration-effect curve was, therefore, repeated at two 
different substrate concentrations (30 and 100 µM). 
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Figure 2.6 The effects of varied BSA concentrations preincubation on 
FAAH-catalysed hydrolysis of oleamide at 100 pM and 30 pM 
using rat liver membrane fractions. Data, conducted in triplicates, 
are expressed as the mean ± SEM from four rat tissues analysed 
using one way ANOVA (*P<0.05). 
Although a complete range of substrate concentrations was not investigated, it 
appears that BSA had more of an effect on the oleamide concentration above the KR, 
(100 µM), than the concentration below the Km (30 µM, Figure 2.6), implying that 
BSA might have increased the Vmax without altering the Km. This could be taken to 
imply that BSA doesn't alter substrate presentation, but increases enzymatic 
conversion, possibly by removing product inhibition. 
2.4.7 Effect of developing reagents in fluorescence generation 
As illustrated in Scheme 2.1, (hydro) sulphite ion reacts with o-phthalaldehyde in the 
presence of ammonia to generate the stable fluorescent isoindole derivative (Rowley 
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et al., 1995; Groves et al., 2005; Kerouel et al., 1997; Westra et al., 2002; Meseguer 
Lloret et al., 2004). As hydrosulphite has a very strong smell and is unpleasant to 
work with in an open lab, the use of sodium sulfite was investigated. 
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Figure 2.7 The effects of fluorescence generation using OPA solutions with 
either hydrosulphite or sodium sulfite reacting with ammonia. 
Data, conducted in triplicates, are expressed as the mean ± SEM 
of three individual experiments. Analysis of data using one way 
ANOVA showed no significant difference between sulfite sources 
on fluorescence development. 
There were no obvious differences in the observed fluorescent Bovine serum albumin 
(figure 2.7) product using sodium hydrosulphite or sodium sulfite, and so subsequent 
investigations employed sodium sulfite in the fluorescence development solution 
with OPA. 
The potential influence of an excess of sulfite on fluorescent product generation was 
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Figure 2.8 The effect of differing OPA: SO3 ratios on fluorescence generation 
from an ammonia standard curve (0-200 nmoles), with 
fluorescence read at 60 min post-addition of OPA/sulfite mix. 
Data, conducted in triplicates, are expressed as mean ± SEM of 
three individual experiments. 
Equimolar ratios of OPA and sulphite in the development buffer showed highest 
levels of detectable fluorescence (Figure 2.8) and longest fluorescent compound 
stability, with little variation in levels of fluorescence between 30,60 and 90 minute 
measurements (data not shown). 
2.4.8 The influence of detergents on FAAH activity 
As FAAH is a membrane-bound enzyme, the effect of detergents, which should 
increase substrate availability, was investigated, investigating different classes of 
detergent. 
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Figure 2.9 The effects of detergents at varied concentrations on FAAH- 
catalysed oleamide hydrolysis at 100 pM, using solubilised rat 
liver membrane fractions. Data, conducted in triplicates, are 
expressed as mean ± SEM from five liver microsome preparations, 
conducted in duplicate. Data analysed using one way ANOVA 
(*P<0.05). 
The presence of all four detergents resulted in a concentration-dependent inhibition 
of enzyme activity (Figure 2.9). However, enzyme activity appeared most sensitive 
to the anionic detergent sodium dodecyl sulphate (SDS), with concentrations as low 
as 0.05 % (- 2 mM) completely inhibiting FAAH activity. Sodium deoxycholate 
(DOC), another anionic detergent, albeit structurally distinct from SDS, was also 
deleterious to FAAH activity, while the non-ionic detergents Tween 20 and Triton X- 
100 were reasonably well tolerated. Concentrations of Triton X-100 less than 0.1 % 
appeared to allow retention of >75 % of enzyme activity, indicating that this 
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combination would be usable in FAAH assays. 
2.4.9 The influence of protein content on FAAH assay 
Using rat liver microsomal preparations at final dilutions of between 0.05 and 0.5 % 
(original wet weight/ volume), the influence of protein dilution on FAAH activity 
was investigated in the novel assay. 
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Figure 2.10 The effects of increased protein concentration of rates of FAAH- 
catalysed oleamide hydrolysis at concentrations of 10 
- 
100 µM 
using rat liver membrane fractions. Data, conducted in duplicates, 
are expressed as the mean t SEM of experiments using four 
different liver preparations. Data were analysed using two-way 
ANOVA with Dunnett's post-hoc test (Protein 0.05% compared 
with 0.25% at 100 pM P<0.05; protein 0.05% compared with 
0.5% at 50 pM P<0.01, at 100 pM P<0.001; protein o. 1% 
compared with 0.5% at 50 pM P<0.05, at 100 pM P<0.01). 
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Increasing protein content evoked a concentration-dependent increase in enzyme 
activity (Figure 2.10) yet there was no significant interaction between protein and 
oleamide concentrations. Results suggest mid to high concentrations of OEA (50 gM 
+) are required to distinguish levels FAAH activity at differing protein 
concentrations, helping to determine an adequate protein concentration for use in the 
assay. The highest concentration of oleamide showed the most linear rates of FAAH 
activity, with increasing concentrations of protein, yet there was no significant 
increase observed in the assay enzyme blanks, showing that increased protein 
concentration in the assay did not cause a significant increase in the background 
noise. 
This method used a test tube-based assay, with transfer of product, to 96-well plates 
to provide a fluorescence assay reading to determine levels of FAAH activity. Assay 
development allowed identification of a useful substrate for use in this assay, 
allowing determination of a measurable level of FAAH activity. Investigation 
identified a range of incubation times that provide high levels of FAAH activity, 
which will lead to further flexibility towards development of a HTS assay 
methodology. Other conditions including substrate preparation materials, assay 
solvent tolerance, sulfite source for fluorescence development buffers and effects of 
detergents and BSA on FAAH activity levels were established, allowing direct 
development of a HTS assay. 
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2.4.10 FAAH HTS assay development 
Inhibition of FAAH leads to an increase in the endogenous tone of endocannabinoids 
(Jhaveri et al., 2008) and, therefore, it is a potential target for various therapeutic 
areas which exploit cannabinoid receptor agonism. However, screening large libraries 
of compounds as potential inhibitors using existing FAAH activity assays would be 
impractical, laborious and expensive. As previously mentioned, the FAAH assay 
development was a precursor to scaling down the assay volumes used, allowing 
inexpensive, facile and rapid HTS of compound libraries for their effects on 
inhibiting FAAH activity, using a 96,384 or 1536-well microtitre plates. 
2.4.11 Preliminary optimisation 
- 
measurement of FAAH activity using a 
microtiter plate assay 
Tissue preparation 
Membrane fragments were prepared from livers of male Wistar rats (150g 
- 
250g) as 
described previously in section 2.2.1. and stored as 1: 10 original wet weight aliquots 
at 
-80 °C. 
FAAH HTS assay method 
FAAH substrates were prepared as 10 mM stock solutions in 100% DMSO. Tissue 
was thawed from 
-80 °C and diluted further to 0.01 gIg wet weight liver (1: 100) using 
0.2M P04 buffer, pH 7.4.25 µL of URB597 (final concentration 5 pM, in 10% 
DMSO) (where 25 pL of 10% DMSO was used in the absence of an inhibitor) or 
other inhibitor screening compounds (final concentration 100 µM) were pre- 
incubated with 25 pL tissue at 37 °C for 15 minutes in a 96-well plate on a plate 
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warmer. 50 µL of ODA (final concentration 100 µM) was added to each well and 
incubated at 37 °C for 30 minutes. The developing buffer (OPA solution) as 
described in FAAH preliminary assay method (section 2.2.1) was prepared and 100 
pL was added to each well to terminate FAAH activity. The 96-well plate was then 
incubated at room temperature for 30 minutes, after which the samples were read at 
wavelengths of ex. 360 em. 490 nm. Enzyme blanks were run alongside the test 
conditions as well as standards using 100 pM ammonium sulphate to allow 
quantification of evolved ammonia. 
ay 
_d =O 
Figure 2.11 Oleamide hydrolysis by FAAH from rat liver preparations (n=4), 
measured following 30 minute and 60 minute incubations at 37°C. 
Data, conducted in triplicates, are expressed as the mean ± SEM and 
analysed using two-way ANOVA. 
As seen in figure 2.11 oleamide hydrolysis measured following 30 minute incubation 
is similar to levels of oleamide hydrolysis seen in the previous assay. There is a loss 
of linearity over the time course and FAAH activity levels seem much lower, albeit 
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non-significant, following a 60 minute incubation, suggesting an optimum time point 
for measurement of maximum oleamide hydrolysis by FAAH in this assay. 
2.4.12 Investigation of the effect of URB597 on FAAH activity using a FITS 
FAAH assay 
To determine the viability of this assay for HTS of FAAH activity, the effect of 
varying concentrations of URB597 on the rate of FAAH hydrolysis of 100 µM 
oleamide was assessed. 
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Figure 2.12 Effects of URB597 on FAAH mediated ODA hydrolysis following 
30 minutes of incubation at 37°C shown as % of control activity (n=3). Data were collected in triplicate values. The table below the 
graph shows quantitative parameters as determined by Prism. 
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Figure 2.13 Effects of URB597 on FAAH mediated ODA hydrolysis following 60 
minutes of incubation at 37°C shown as % of control activity. 
The table below the graph shows LogEC50 values for each 
independent tissue tested (n=3). 
The effects of URB597 (figure 2.12 and figure 2.13) indicate that ODA hydrolysis 
was fully inhibited at both 30 and 60 minute time points with 1x 10-6 M URB597. 
This compares well with our previously described method which showed URB597 to 
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fully inhibit 100 µM ODA hydrolysis in a larger format assay. LogEC50 values were 
- 
6.35 for both time points, which compares well to the previously described method. 
2.4.13 The effects of TX-100 on FAAH activity 
The use of detergents in biochemical assays is useful to ensure cell lysis and facilitate 
substrate access to membrane-associated enzymes (Qui et al., 2008). The effect of 
TX-100 in solubilisation of the enzyme was investigated to assess it's influence on 
FAAH activity in the assay. 
We compared the effects of Triton X-100 using unsolubilised membranes, 
membranes exposed to detergents (using 0.01% TX-100 (v/v)) on ice for 30 minutes 
and post-hoc tissue exposure, where 0.01% TX-100 (v/v) was added with the 
development buffer (OPA solution). 
TX-100 enzyme solubilisation method 
An aliquot of membrane fraction was thawed and solubilised with 0.01% TX- 100 on 
ice for 30 min. Following centrifugation at 20 000 g for 15 minutes, the supernatant 
layer was decanted and diluted a further 1: 10 in 0.2 M phosphate buffer, pH 7.4, 
containing I mM ethylenediaminetetraacetic acid (EDTA). 
TX-100 post-hoc enzyme solubilisation method 
Development buffer (5 mM OPA, 5 mM sodium sulfite, 0.4 M potassium phosphate 
buffer, pH 11.4) was made up including 0.01% TX-100 (v/v), and then used to halt 
the enzyme substrate incubation. 
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FAAH HTS assay method 
Assay volumes previously described were changed to 5 µL inhibitor (URB597, final 
concentration 5 µM), 20 µL ODA (final concentration 100 µM) and 75 µL tissue. 
100 pL OPA solution was used post-incubation. 
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Figure 2.14 Effects of TX-100 detergent based enzyme solubilisation on levels 
of FAAH activity. Comparing levels of inhibitable FAAH by 
URB597 in pre solubilised enzyme, post-hoc solubilised enzyme 
and neat enzyme preparations prepared from rat liver tissue. 
Data are means ± SEM for three independent preparations 
assessed in triplicate (n=4). LogEC50 values were 
-7.3, -7.9 and -8.0 
for the solubilised, unexposed and post-hoc solubilised enzymes 
respectively. 
Figure 2.14 indicates that prior solubilisation of liver membranes with 0.001 % TX- 
100 leads to recovery of similar levels of FAAH activity as using membranes without 
solubilisation. However, solubilisation resulted in a decrease in potency of URB597 
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and there was no difference in fluorescence readings between unexposed enzyme and 
post-hoc solubilised enzyme. 
2.4.14 The influence of DMSO on the FAAH assay 
Our previous studies indicated ODA to be soluble in 1% DMSO up to 100 µM, while 
concentrations above this required higher DMSO concentrations. Since other 
compounds used to test FAAH inhibition using this HTS method may also require 
higher solvent concentrations, we investigated the influence of DMSO (0-30%) on 
FAAH activity. 
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Figure 2.15 Effects of varying concentrations of DMSO on FAAH activity 
(using 100 pM ODA, in the absence and prescence of two 
67 
concentrations of FAAH inhibitor URB597. Data are expressed 
as means ± SEM of 3 individual experiments, conducted in 
triplicate (n=3). 
As shown in figure 2.15 concentrations of DMSO up to 30%-were well tolerated in 
this HTS FAAH assay, allowing us the use of large libraries of compounds to be 
screened as inhibitors of FAAH, not limited by their level of solubility. 
This method used a 96-well plate-based method to allow high throughput screening 
of FAAH activity. Results indicated high rates of FAAH mediated oleamide 
hydrolysis following 30 minutes of incubation which were similar to levels measured 
in previous assays. At 60 minutes FAAH mediated oleamide hydrolysis was still 
detectable but rates were much lower compared to 30 minute incubations for reasons 
which remain unclear. A 30 minute incubation period is more favourable in allowing 
greater throughput in screening. This method displayed more sensitivity to URB597, 
with logEC5o values of 
-7.9 in untreated enzyme sources compared to previous assay 
experiments, using the same enzyme preparation methods, where logECso values of 
URB597 were 
-6.3. Results indicate that solubilisation of enzyme sources provide no 
further benefit toward FAAH hyrolysis in this method, therefore unexposed (neat) 
enzyme shall be used in future. The assay also showed excellent tolerance of the 
common solvent DMSO (used widely for screening compound solubilisation). 
DMSO tolerance of up to 20% allows for a much bigger range of compound use. 
These data clearly show that this assay can successfully be used for the HTS of 
compound libraries as potential FAAH activity inhibitors. 
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2.4.15 Application of HTS FAAH assay: Compound screening to investigate 
potential inhibitors of FAAH activity 
The effects of groups of known compounds on the hydrolysis of 100 µM oleamide by 
rat liver FAAH were examined using the HTS FAAH assay methodology. On each 
96-well plate, test compounds were arranged in columns of 8, assessing FAAH 
activity in four different liver preparations. For each preparation, one well was a test 
which contained compound, enzyme and substrate. In the other well of the pair, 
compound and enzyme were mixed but substrate was only added after OPA 
development solution, to provide a test compound blank. Thus, the two wells 
contained identical mixtures and differed only in the 30 minute incubation period 
allowing enzymatic hydrolysis of the ODA. The screening method assessed FAAH 
hydrolysis of ODA at a final concentration of 100 µM, with final solvent 
concentration (DMSO) at 10%. Each test compounds blank value was subtracted 
from its test value, the percentage inhibition of oleamide hydrolysis by each 
compound was calculated as a percentage of the control level of FAAH activity on 
each individual plate. The mean ± range percentage inhibition was then calculated. 
The results from this screen are shown in figure 2.16. 
2.4.16 FAAH activity HTS assay method 
Tissue preparation 
Membrane fragments were prepared from livers of male Wistar rats (150g 
- 
250g) as 
described previously in chapter 2.2.1, and stored as 1: 10 original wet weight aliquots 
at 
-80 °C. 
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FAAH HTS assay method 
Fresh oleamide was prepared as 10 mM stock solutions in 100% DMSO. Four sets of 
rat liver tissue sources for FAAH activity were thawed from 
-80 °C and diluted 
further to O. O1gIg wet weight liver (1: 100) using 0.2M P04-EDTA 5mM buffer pH 
7.4.25 µL of URB597 (final concentration 5 µM, in 5% DMSO) or 25 µL of 
inhibitor (final concentration of 100 pM in 5% DMSO) were pre-incubated with 25 
µL of each tissue at 37 °C for 15 minutes in a 96-well plate on a plate warmer. 
Corresponding blanks (n=4) were set-up for each inhibitor compound, without ODA, 
where 50 µL of ODA (100 µM) was added to each well post-incubation. To all wells 
with test inhibitors, ODA was added and incubated at 37 °C for 30 minutes. The 
developing buffer (OPA solution as described in FAAH preliminary assay method 
chapter 2.2.1) was prepared and 100 pL was added to each well to terminate FAAH 
activity. The 96-well plate was then incubated at room temperature for 30 minutes, 
after which the samples were read at wavelengths of ex. 360 em. 490 nm. Enzyme 
blanks were run alongside the test conditions as well as standards using 100 µM 
ammonium sulphate to allow quantification of evolved ammonia. 
2.4.17 Application of FAAH HTS assay: HTS of compounds as potential FAAH 
inhibitors 
The following graphs show results of a high throughput screening of a large group of 
compounds. FAAH activity is indicated as % of control oleamide hydrolysis. For 
those samples exposed to URB597, FAAH activity was not different from tissues 
blanks. 
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Figure 2.16 FAAH HTS of cannabinoid ligands as potential inhibitors. 
Cannabinoid ligands were screened as potential inhibitors at 100 
µM, and their effect examined on FAAH hydrolysis of 100 pM 
oleamide. URB597 was used as an inhibitor standard. Data were 
collected in single replicates (n=4). Data were analysed using one- 
way AVOVA (***P<0.001). 
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Figure 2.17 FAAH HTS of natural products as potential inhibitors. Natural 
products were screened as potential inhibitors at 100 µM, and 
their effect examined on FAAH hydrolysis of 100 µM oleamide. 
URB597 was used as an inhibitor standard. Data were collected in 
s (n=4). Data were analysed using one-way AVOVA 
(***P<0.001; **P<0.01; *P<0.05). 
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Figure 2.18 FAAH HTS of NSAIDs as potential inhibitors. NSAIDs were 
screened as potential inhibitors at 100 µM, and their effect 
examined on FAAH hydrolysis of 100 pM oleamide. URB597 was 
used as an inhibitor standard. Data were collected in single 
replicates (n=4). Data were analysed using one-way AVOVA 
(***P<0.001; **P<0.01; *P<0.05). 
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Figure 2.19 FAAH HTS of miscellaneous compounds as potential inhibitors. 
Miscellaneous compounds were screened as potential inhibitors at 
100 pM, and their effect examined on FAAH hydrolysis of 100 MM 
74 
oleamide. URB597 was used as an inhibitor standard. Data were 
collected in single replicates (n=4). Data were analysed using one- 
way AVOVA (***P<0.001; **P<0.01; *P<0.05). 
Results above show successful application of a HTS assay for FAAH activity using 
96-well plates. The assay allows for screening of 10 inhibitors and URB597 per 96- 
well plate, with each plate screened in 75 minutes from start to final reading and by 
running four parallel plates for each 75 minute cycle, it is possible to screen 250 
compounds without the use of robotics. Results indicate good sensitivity to URB597, 
where blanks were seen to be no different than URB597 treated wells For some 
compounds, blanks were higher due to the colour or fluorescence of the compound. 
For example, resazurin, which is deep blue, curcumin, which has a brown colour and 
7-amino-4-methylcoumarin, which is a highly planar fluorescent compound. FAAH 
activity rates and the variation between potential inhibitors are clearly represented 
visually. The cannabinoid compounds showed little effects on rates of FAAH 
activity, with capsacin producing the only significant reduction (figure 2.16). Rates 
of FAAH inhibition allow a structure-activity relationship to be suggested. Some 
have been observed in this screen, mainly within the group of NSAIDs and flavones. 
There were various compounds shown in figure 2.17 which significantly inhibit 
FAAH activity, for example dopamine, amiloride and captopril, none of which are 
structurally related and therefore do not lend themselves towards development of 
structure activity related effects on FAAH as inhibitors. 
Results clearly show that the HTS FAAH activity assay can be applied to screen 
compound libraries of potential inhibitors in industry to easily identify new FAAH 
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inhibitors compared to known FAAH inhibitor URB597 and with the use of ODA as 
FAAH substrate. 
2.4.18 Application of FAAH HTS assay: further investigation into potential 
FAAH inhibitor compounds 
The compounds screened as potential FAAH inhibitors showed no trend within 
groups of compounds, and inhibition of FAAH observed within the results in chapter 
2.4.2 was compound specific. We looked at each compound individually and further 
investigated compounds that inhibited activity by greater than 55% by conducting a 
concentration-response of each compound, at concentrations of 1x 10"6 
-1x 104, to 
obtain an estimate of potency as a potential FAAH inhibitor. 
2.4.19 FAAH activity HTS concentration-response assay method 
Tissue preparation 
Membrane fragments were prepared from livers of male Wistar rats (150g 
- 
250g) as 
described previously in chapter 2.2.1 and stored as 1: 10 original wet weight aliquots 
at 
-80 °C. 
FAAH HTS assay method 
The assay was conducted as described in section 2.4.1. 
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2.4.20 Further investigation (concentration-response curves) of compounds a 
potential inhibitors of FAAH activity 
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Figure 2.20 Concentration response curves on all compounds exhibiting <40% 
control in HTS screen. All compounds screened at 10'4-10' log M. 
Data collected in single replicates, n=4, data are expressed as % 
control. 
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Compound lo EC50 SEM 
rutin 
-4.5 0.3 
kaempferol 
-4 0.3 
fisetin 
-4.7 0.5 
capsacin 
-4.6 0.2 
VDM11 
-4.9 0.1 
HP108 
-4.5 0 
Nimesulide 
-4.5 0 
Tolmetin 
-5.9 0.4 
5-sulfosalicylic 
-4.9 0.8 
NS398 
-4.5 0.1 
Piroxicam 
-5.1 0.3 
RHC80267 
-4.5 0.3 
ca to ril 
-5.5 0.5 
Table 2.2 LogEC50 values of all potential inhibitors of FAAH activity. This 
table displays the mean logECsa value obtained for each obtained 
from four replicates, with the last row displaying standard error 
of the mean. 
In comparison with URB597 (IogEC50 of 
-6.35), none of the further investigated 
compounds as FAAH inhibitors in section 2.5 were as potent. This experiment shows 
that potential inhibitors can be further investigated to obtain logEC50 values which 
allow for a point of comparison with the known logEC5o of the selective FAAH 
inhibitor URB597. This will help to rapidly determine whether any compounds 
would potentially provide a stronger level of inhibition compared to that provided by 
URB597. 
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2.4.21 Z-Factor 
The Z-factor is a statistical analysis and measure of the size of effect within a given 
assay. It has been used in high throughput assays, used for multiple compound 
screening, to determine whether the response in an assay is large enough to warrant 
further attention, and provides an indication of the quality of the assay itself [Zhang 
1999]. The final Z-factor value reflects both the assay signal dynamic range as well 
as the data variation associated with the signal measurements and therefore provides 
a through assay quality assessment. It is a value which clearly aids the process of 
assay optimization. 
Calculation 
Calculation of the Z-factor requires input of four parameters, the means and standard 
deviations of both positive (p) and negative (n) controls (Xp. (and y,,. an). 
Given these values the Z-factor is defined by: 
Z-Factor = 1- 3x (ap+an)/ (Xp. X) 
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Interpretation 
Z-Factor Interpretaion 
1.0 Ideal. Z-Factor can never exceed 1. 
0.5-1.0 Excellent assay. 
0-0.5 Marginal assay. 
less than 0 Too much overlap of positive and negative control for assay to be useful. 
HTS FAAH assay calculation 
positive negative 
control control 
(ODA) (URB) 
13208 
-66 
15554 
-241 
20999 403 
19913 181 
19578 456 
18534 
-212 
17964 28 
mean 17964 78 
st dev 2518 259 
Factor 0.53 
Table 2.3 Z-factor value calculated using data from HTS FAAH inhibitor 
screening, with the use of 100 µM ODA and 5 µM URB597. 
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2.5 Discussion 
This chapter describes the characterisation of a novel fluorescence-based 96-well 
plate high throughput FAAH activity assay to provide a cheap and rapid assay tool 
for use in industry towards the development and identification of potential FAAH 
inhibitors. Application of this assay was successful in identification of potential 
FAAH inhibitors, and provided an easy route for further investigation to determine 
the potency of the potential inhibitors picked out from an initial screen. It has few 
additions and can therefore be easily applied to industrial lab robotics, with raw data 
easily manipulated by computer macro applications allowing for fast identification of 
potential inhibitors within a large library of screened compounds. Tolerance of the 
assay to high concentrations of solvents, used to solubilise compounds, provide 
further flexibility in the range of compounds that can be used and screened in the 
assay, with URB597 as a useful tool for comparison of new and potential inhibitors. 
Using this methodology the KM and VM, values for FAAH-catalysed oleamide 
hydrolysis were determined and found to be similar to that obtained in using the 
previous non-HTS methodology. In addition, inhibition of FAAH by URB597 was 
observed in a concentration-dependant manner with similar IC50 values obtained 
using the previous methodology. We have seen that pre-incubation is necessary in 
application of this assay towards potential new inhibitors, as there was an increased 
sensitivity when URB597 was pre-incubated for 15 minutes prior to addition of 
substrate. It was shown that there was no difference in the use of pre or post-hoc 
solubilised enzyme preparations, therefore provides a simpler and quicker option and 
preparation of an enzyme source. The Z-factor calculation (Z-Factor = 0.53) (table 
81 
2.3) also provides an indication of a very useful assay in the use of HTS screening 
towards the identification of potential inhibitors of FAAH. 
2.5.1 The HTS Assay 
Figure 2.16 shows the majority of the cannabinoid compounds failed to significantly 
affect FAAH activity. Capsaicin is a vanniloid receptor TRPV I agonist, which may 
stimulate eCB generation through calcium mobilization. Figure 2.16 shows its use at 
100 µM is high enough to activate TRPVI receptors and also cause FAAH inhibition. 
These two independent effects may lead to an even further increase in endogenous 
levels of eCBs potentially contributing to capsaicin-evoked analgesia. This 
possibility requires testing in intact cells, such as dorsal root ganglion cells. 
AEA and cannabidiol (CBD) have been reported to divert or inhibit FAAH activity, 
where the IC50 of CBD has been reported to be 27.5 µM (Bisogno et al., 2001). Our 
assay provided adequate concentrations of CBD to cause such an inhibition on 
FAAH, yet inhibition of its activity was not observed in figure 2.16. 
Figure 2.17 allows assessment of structure: activity relationships amongst the 
flavonoids as FAAH inhibitors to be identified. For example, glycosylation, 
compound saturation and hydroxylation are potential influences on FAAH inhibitory 
activity. Flavone has a C2 
- 
C3 double bond, whereas flavanone is unsaturated in its 
structure. Neither compound exhibited significant inhibition of FAAH activity 
(FAAH activity (% control) = 90 ± 17 and 111 ± 19, respectively). Rutin, a 
glycosylated derivative of quercetin, seemed as effective as quercetin itself. The 
soya-derived isoflavone genistein was more effective than it's flavones isomer 
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apigenin (4', 5,7-trihydroxyflavone) (44 % vs. 92 %). In summary, though, there was 
no clear-cut pattern allowing the identification of the importance of hydroxylation 
number or position on inhibition of FAAH activity. Chris Fowler's group have 
previously established SAR to the favonoids on their inhibition of FAAH. 
Kaempferol was reported to be the least potent 
, 
displaying FAAH inhibition, using a 
radiolabelled AEA hydrolysis assay, with a Ki value of 5 µM. 7-hydroxyflavone and 
3,7-dihydroxyflavone were amongst the most active, displaying IC50 values of 1 µM 
and 2.2 µM respectively (Thors et al., 2008). Our results correlate with this study, as 
seen in figure 2.17, we observed the most potent effect on FAAH activity to be by 
3,7-dihydroxyflavone, which was more potent compared with 7-hydroxyflavone. 
Kaempferol inhibited FAAH activity with a value in between that of the above 
hydroxyflavones. Fowler's group conducted their study using radiolabelled AEA 
hydrolysis, which is widely regarded as the current gold standard for measuring 
FAAH activity, although it doesn't allow the high-throughput of our HTS FAAH 
assay. It will clearly be vital to determine whether methodological differences in the 
assays are responsible for these discrepancies in inhibitor potency.. 
Flavonoids are present in the diet and are ingested daily in our diets. They are present 
at pM concentrations in plasma and from our data in table 2.3 we see that 10+ pM 
concentrations are required to produce an inhibitory effect on FAAH activity. It 
appears unlikely, therefore, that individual dietary flavonoids will influence FAAH 
activity levels significantly, although, but it may be possible for several flavonoids to 
have additive effects on FAAH inhibition, especially if their mechanisms of FAAH 
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inhibition differ from each other 
- 
producing a more potent effect overall. 
Although the compounds itemised in table 2.2 are less potent inhibitors when 
compared with URB597, they may well still provide therapeutic benefit. Lower 
potency as a FAAH inhibitor may provide lower levels of eCBs available for CB 
receptor activation. Low level cannabinoid receptor activation has been reported to be 
beneficial in disease (for example in the treatment of MS (Baker et al., 2001). 
There are no existing studies in the literature to match the screening conducted here, 
although some individual compounds have been reported to inhibit FAAH activity, in 
particular the NSAIDs. Fowler's group have previously shown the COX inhibitor 
ibuprofen to inhibit FAAH activity, while the COX2 inhibitor nimesulide was 
inactive (Fowler et al., 2003). Our findings (figure 2.18) show no significant levels 
of FAAH inhibition, compared with control. Differences in the methodologies may 
have caused these different findings, as suggested above. 
In summary, it appears likely that this assay will provide a highly useful tool to 
extend cannabinoid research as there is growing interest in the therapeutic use of 
FAAH inhibitors. 
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Chapter 3: Development of MAGL HTS assay 
3.1 Introduction 
Monoacylglycerol lipase (MAGL) is a key enzyme in the hydrolysis of the 
endocannabinoid 2-arachidonoylglycerol (Dinh et al., 2002; Makara et al., 2005). It 
converts monoacyiglycerols to the free fatty acid and glycerol. 2-AG is a naturally 
occurring monoglyceride that acts as a full agonist at both cannabinoid receptors and is 
present in the brain (Mechoulam et al., 1995) (Sugiura et al., 2006). Levels of 2-AG in 
the brain have been found to be 170-fold higher than those of anandamide. It is produced 
by neurons in an activity- and calcium-dependent manner, and is rapidly eliminated 
(Stella 1997). The contribution of MAGL to total brain 2-AG hydrolysis activity has been 
estimated to be 
-85% (Blankman et al., 2007). This in vitro estimation of MAGL activity 
has recently been confirmed in vivo with the use of a selective MAGL inhibitor JZLl84 
The subcellular localisation of MAGL was first studied in rat adipocytes, where the 
enzyme activities were mainly found in the plasma membrane and in the cytosol fractions, 
with activity levels being similar between the two fractions (Sakurada and Noma, 1981). 
It was originally found to function with hormone-sensitive lipase (HSL) in the hydrolysis 
of adipocyte triglyceride stores (Fredrikson et al., 1986), which led to the investigation of 
its ability to hydrolyse other monoglycerol compounds, such as 2-AG and its analogues. 
Previously used methods to determine MAGL activity involve measurement of free fatty 
acid release from a monoacylglycerol substrate using a gas or liquid chromatography 
mass spectrometry (GC/LC-MS) system or measurement of radiolabelled substrate 2- 
85 
oleoyl-[3H]-glycerol. 
The radiolabelled substrate assay is the most commonly used. It allows the labelled 2-OG 
to react with either use of cytosolic of membrane bound enzyme preparations for a set 
period of time. The reaction is then stopped using either charcoal (Boldrup et al., 2004) or 
the Folch extraction procedure based on the use of 1: 1 aqueous/organic mixtures, in this 
case, methanol: chloroform, which allows separation of the hydrophilic and lipophilic 
fractions (Folch et al., 1957). Pure chloroform is then used to bring the aqueous phase to 
the top, which contains the radiolabelled hydrophilic glycerol moiety release following 
hydrolysis by MAGL. The free fatty acid moiety remains in the organic phase along with 
any unhydrolysed 2-OG, providing complete separation of the hydrolysed product. The 
amount of hydrolysed 2-OG is then measured using liquid scintillation spectroscopy 
(Dinh et al., 2002) (Omeir et al., 1995). Methods using LC-MS commonly estimate 2-AG 
as a MAGL substrate and amounts of arachidonic acid (AA) cleaved off from 2-AG 
hydrolysis by MAGL. The released AA is then measured by GCILC-MS. (Muccioli and 
Stella, 2008). Both methods are laborious and time consuming. Even though the 
radiolabelled assay is more sensitive and accurate in the measurement of monoglycerol 
hydrolysis by MAGL compared with the GC/LC-MS methodology and can be used in a 
96-well format (Brengdahl and Fowler, 2006), the use of radiolabelled substrates has the 
drawback of being expensive. 
The most recently developed assay used to measure MAGL activity is a colorimetric 
assay (Muccioli and Stella, 2008) using recombinant human MAGL (Labar et al., 2007). 
It is a simple and inexpensive method that can be applied to high throughput screening of 
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potential inhibitors of MAGL with the use of a chromogenic substrate 4- 
nitrophenolacetate (4-NPA). Hydrolysis of substrate following incubation with 
recombinant enzyme results in development of a yellow colour which allows kinetic 
measurement over time to measure 4-NPA hydrolysis. A drawback to this assay is that 
NPA 
. 
is not a specific substrate for MAGL and thus 4-NPA hydrolysis activity will be 
influenced by other non-specific esterases. Hence, the radiolabelled assay may be used 
alongside the colorimetric assay to determine, confirm and quantify the level of MAGL 
activity (using the MAGL inhibitor MAFP) and determine the contributed activity from 
non-specific esterases. 
We have applied Muccioli's method towards native tissues, to investigate it's potential as 
a more accessible and cheaper HTS assay for potential inhibitors of MAGL. 
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3.2 Method 
3.1.1 Tissue preparation 
Membrane and cytosolic fragments were prepared from various tissues of male Wistar 
rats (150g 
- 
250g) as described previously in chapter 2.2.1. and stored as 1: 10 original 
wet weight aliquots at 
-80 °C. Homogenate preparations of tissues were also stored at -80 
oc 
3.1.2 Preliminary MAGL HTS assay method 
4-NPA was prepared as 100 mM stock solutions in 100% EtOH and stored at 
-20 °C. 
Tissue was thawed from 
-80 °C and diluted further to 0.01 g/g wet weight tissue (1: 100) 
using 50 mM Tris-EDTA buffer, pH 7.4. Concentration response curves were generated 
using 10 "1 to 10-4 NaF as an esterase inhibitor, with and without the presence of 1 µM 
MAFP (in 10% DMSO) or other inhibitor screening compounds (100 µM) were pre- 
incubated with n=4 of enzyme source at 37 °C for 15 minutes in a 96-well plate on a plate 
warmer. 250 pM NPA was added to each well, making an assay volume of 200 ML. 
Colour development as a result of 4-NPA hydrolysis was measured kinetically at a 
wavelength of 405 nm on a spectrophotometer for 60 minutes. Data generated after 15 
minutes were isolated and analysed. 
3.1.3 Data Analysis 
Following kinetic measurement of 4-NPA hydrolysis, data were extracted at a time point 
of 15 minutes. 4-NPA hydrolysis with MAFP alongside a NaF concentration curve was 
deducted from 4-NPA hydrolysis with NaF levels providing baseline data, which was 
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then normalised to control 4-NPA hydrolysis without presence of inhibitors and 'graphs 
were generated as % of control activity, with log IC50 values calculated. 
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3.3 Results 
3.2.1 Comparison of skeletal muscle and adipose tissue as a source of MAGL 
activity 
As discussed in section 2.1 both skeletal muscle and adipose tissue have previously 
shown levels of MAGL activity. Here we investigated levels of MAFP inhibitable 
activity in the presence of the non-specific esterase inhibitor NaF, from soluble, 
particulate and homogenate tissue preparations. We collected Wistar rat (150-250 g) 
adipose tissue and skeletal muscle from the thigh and prepared it as in section 2.2. We 
used dilutions of tissue preparations determined in preliminary investigations to give 
maximal substrate hydrolysis levels from each tissue fraction. Cytosolic preparations 
were diluted 1: 10, particulate preparations were diluted 1: 40 and homogenate, showing 
highest levels of activity was diluted to 1: 50. 
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Figure 3.1 MAGL activity as determined by NPA hydrolysis in rat adipose (a) 
and rat skeletal muscle tissue (b), in soluble, particulate and 
homogenate fractions against a concentration response curve of NaF. 
Data were collected using four tissue preparations, conducted in 
triplicate and expressed the mean ± SEM then analysed using one-way 
-+- homogenate 
-- 
particulate 
t soluble 
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ANOVA with Dunnett's post-hoc test. 
log IC50 (IoM) 
Mean 
(1o M) 
Adipocyte 
-2.41 -2.86 -2.52 -2.6 
Skeletal 
-2.38 -2.49 -2.41 -2.43 
Table 3.1. Log ICso values of 4-NPA hydrolysis by NaF in both adipocyte and 
skeletal muscle tissues, using homogenate, particulate and cytosol 
(from left to right, respectively). 
Analysis of data show activity from all fractions of adipocyte tissue, as a source of 
MAGL activity, to be higher than observed in skeletal muscle. Log IC50 values calculated 
for NaF (table 3.1) were reasonably consistent in adipose and skeletal muscle tissue. 
MAGL activity was highest in the adipose particulate fraction, providing the lowest log 
IC50 value (-2.86) where log IC50 values for both soluble and homogenate fractions were 
similar (-252 and 
-2.41 respectively). 
Results suggest a higher level of MAGL activity in adipose tissue, which is suggested in 
literature, yet a direct comparison between both sets of tissues, under the same 
conditions, has not previously been done. There is also a higher potency of MAGL 
activity inhibition with NaF in the particulate fractions of adipose tissue, compared to 
soluble and homogenate preparations, suggesting easier access of NaF to MAGL. This 
was unexpected as it is well documented that MAGL is primarily a cytosolic enzyme and 
therefore access of inhibitors should be greater in the soluble fractions ((Somma-Delpero 
et al., 1995) 25mM NaF=10% control MAGL activity). 
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3.2.2 The effects of SDS on adipose tissue NPA hydrolysis 
To try to isolate the MALL component of NPA hydrolysis, the effects of the detergent 
SDS were examined in adipose tissue preparations. 
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Figure 3.2 MAGL activity in rat adipose tissue soluble, particulate and 
homogenate fractions with SDS. MAGL-dependent NPA hydrolysis 
was defined by the presence of 1 pM MAFP. Data were collected using 
four tissue preparations, conducted in triplicate and expressed the 
mean ± SEM then analysed using one-way ANOVA with Dunnett's 
post-hoc test. 
Figure 3.2 shows completely diminished MAGL activity following enzyme 
solubilisation with 0.01 % and 0.001 % SDS in all adipose tissue fractions. 
MAGL solubilisation should make the suggested plasma membrane location of MAGL 
(Sakurada and Noma, 1981) more accessible for substrate hydrolysis. Following enzyme 
solubilisation, we would expect similar or increased levels of MAFP inhibitable activity. 
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Figure 3.2 suggests 4-NPA is not hydrolysed by solubilised enzymes. Previous studies 
assessing lipase activity (hormone-sensitive lipase) from adipocyte preparations have not 
been successful due to interactions of enzymes with lipid, producing large lipid-protein 
aggregates, which would cause major light scattering when used in our assay. This group 
also encountered difficulties when trying to extract lipids with solvents of detergents 
(Fredrikson et al., 1986). This problem then led into detergent-based solubilisation of 
adipocyte tissue preparations which then allowed for HSL solubilisation and partial 
purification to use as an enzyme source. Solubilisation of MAGL was achieved by 
Torngvist and Belfrage (1976) using apolyoxyethylene alcohol detergent which did not 
cause changes in biological activity. They found attempts at solubilisation of homogenate 
with sonication at various combination of ionic strength and pH without detergent was 
not successful. The non-ionic detergent nonipol was therefore used for solubilisation. 
This group also identified that protection of the functional sulfhydryl groups of MAGL 
increased stability of enzyme activity. 
We observed complete loss of biological activity in the presence of the anionic detergent 
SDS, which suggests disruption of the structure of the enzyme, for example, by 
interfering with sulfhydryl groups. Use of non-ionic detergents may prove to be a more 
successful approach. 
3.2.3 Adipose tissue as a source of MAGL activity 
We investigated levels of NPA hydrolytic activity in adipose tissue using different 
dilutions of the particulate fraction. We extracted rat adipose tissue from three male 
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Wistar rats (150-200 g), and tissue was prepared as in section 3.2. 
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Figure 3.3 MAGL activity in rat adipose particulate fractions at a range of tissue 
dilutions, with and without 1 µM MAFP. Data were collected using 
four tissue preparations, conducted in triplicates and expressed the 
mean t SEM then analysed using one-way ANOVA with Bonferroni's 
post-hoc test (***p<0.001). 
Figure 3.3 shows 4-NPA hydrolysis is present in all three adipose particulate dilutions, 
with activity being the highest in the least diluted preparation (1: 20) which displays 
highly significant levels of MAFP inhibitable activity (MAGL-specific), with clearly a 
high level of activity still present from other esterases. 1: 80 dilution of the particulate 
also displays a high level of 4-NPA hydrolysis, albeit lower than 1: 20 diluted tissue, yet it 
shows a very low level of MAFP inhibitable activity which is not significant. The 1: 40 
dilution of adipocyte particulate provides the lowest amount of 4-NPA hydrolysis of the 
three tissue dilutions, yet it appears to have the greatest contribution of MAFP inhibitable 
activity, with the least influence of other esterases. 
Figure 3.3 shows a 1: 40 dilution of adipocyte particulate tissue to be the most favourable 
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to apply to the HTS MAGL assay, as there is a high level of MAFP inhibitable activity, 
which displays MAGL specific 4-NPA hydrolysis. This tissue preparation provides the 
lowest levels found of 4-NPA hydrolysis resulting from other esterases. The description 
of the recent MAGL colorimetric assay by Muccioli (2008) suggests that non-specific 
esterases this MAGL specific activity difficult to determine in native tissues. Hence, the 
lower the levels of NSE activity we have, the easier it is to determine a MAGL specific 
effect. Results shown in figure 3.3 were generated from the same experiment, where the 
same tissues were used and diluted to be run directly in the experiment. However, the 
unusual pattern of MAFP-inhibitable activity observed, where activity at the greatest- 
dilution appeared to derive entirely from NSEs, while only a 2-fold more concentrated 
protein preparation appeared to be entirely due to MAGL activity, suggests some 
complex interactions. Experiments previous to this, which were run to determine optimal 
protein dilutions in adipose particulate preparation showed a variety of sensititivity to 
MAFP, indicating adipose tissue may not be suitable without additional manipulation as a 
MAGL source for application in a high throughput spectrophotometry assay. 
3.2.4 Brain tissue as a source of MAGL activity 
We therefore investigated the use of a more traditional source for ECB turnover, rat brain 
cytosol (Dinh et al., 2002); (Blankman et al., 2007). Rat brain cytosol is used in 
radioligand assays for 3H-2-OG hydrolysis by MAGL (Ghafouri et al., 2004). In the right 
conditions, it was anticipated that there should be an abundance of MAGL activity in this 
tissue preparation for high throughput application. 
Tissue fractions were kept in 1: 10 w/v stock at 
-80°C and then further diluted according 
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to the tissue fraction. Homogenate was further diluted 1: 50, particulate 1: 10 and cytosol 
1: 40, to assess all fractions from the rat brain for preliminary levels of MAGL present. 
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Figure 3.4 Levels of 4-NPA hydrolysis by MAGL in rat brain homogenate, 
particulate and cytosolic preparations, and the influence of varying 
concentrations of NaF. Data were collected using four tissue 
preparations, conducted in triplicates and expressed the mean ± SEM. 
Data were normalized and expressed as percentage of control MAGL 
activity. 
Homogenate Particulate Cytosol 
Log 
EC50 
-2.02 -1.93 -1.93 
Table 3.2. Log EC50 values calculated using sigmoidal dose response (variable 
slope) of MAGL 4-NPA hydrolysis in rat brain homogenate, 
particulate and cytosolic fractions. 
Results show high levels of MAGL activity in the rat brain, which is inhibitable by NaF 
at log EC50 values of between 
-2.02 and -1.93. Intriguingly, the cytosolic fraction 
appeared to be inhibited by NaF more than homogenate and particulate fractions. 
The effects of MAFP were investigated on rat brain cytosolic NPA hydrolysis, to attempt 
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to define the contribution of MAGL. 
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Figure 3.5 Levels of 4-NPA hydrolysis in rat brain cytosol preparations, and 
MAFP inhibitable levels (a) Concentration-response curve of NaF on 
4-NPA hydrolysis in rat brain cytosol preparations with and without 
MAFP (b). Data were collected in triplicates and expressed the mean 
t SEM of three individual experiments then analysed using one-way 
ANOVA with dunnett's post-hoc test. 
1: 20 1: 40 1: 80 
control 
-2.52 -2.38 -2.48 
+ MAFP 
-2.55 -2.24 -2.20 
Table 3.3 Log EC50 values obtained for 4-NPA hydrolysis (control) in the 
presence of MAFP (+ MAFP) alongside a NaF concentration gradient 
(10"1-10-4) using rat brain cytosolic fractions at differing dilutions. 
Figure 3.5 indicates that NPA hydrolysis by rat brain cytosol was not greatly affected by 
dilution of the tissue over the range 1: 20 to 1: 80. At all three dilutions, MAFP was 
without significant effect. Neither did MAFP alter the effects of different concentrations 
of NaF, which were complex. 
Since these results were not consistent with evidence from the literature and the labs at 
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Nottingham for high levels of MAGL activity in the rat brain cytosol, the use of the more 
traditional radiometric assay for MAGL activity was investigated. 
3.2.5 MAGL inhibition by NaF 
- 
radiometric assay 
Although NaF appears to be an inhibitor of NPA hydrolysis in multiple tissues, it would 
be useful to determine whether NaF has any direct inhibition of MAGL. 
Tissue preparation 
Cytosolic fractions were prepared from various tissues of male Wistar rats (1508 
- 
250g) 
as described previously in chapter 2.2.1. and stored as 1: 10 original wet weight aliquots 
at 
-80 °C. 
MAGL radioligand binding assay (3H-2-OG) 
Tissue was thawed from 
-80 °C and diluted further to 0.01 g/g wet weight tissue (1: 100) 
using 50 mM Tris-EDTA buffer, pH 7.4. Enzyme source was pre-incubated with NaF and 
MAFP, as required, at 37 °C for 15 minutes in 0.5 mL Eppendorf tubes. 100 µM 3H-2- 
OG was added to each tube, making an assay volume of 100 ML. These were incubated in 
a water bath for 30 minutes at 37 °C and then stopped using 200 µL of a 1: 1 mixture of 
methanol: chloroform, followed by the addition of 200 pL chloroform to allow separation 
of the upper aqueous layer containing radiolabelled glycerol. 100 µL of this layer was 
removed and added to 3 mL scintillation fluid and counted overnight. 
Data Analysis 
Following scintillation counts of radiolabelled sample content. 3H-2-OG hydrolysis with 
MAFP alongside a NaF concentration curve was deducted from 3H-2-OG hydrolysis with 
99 
NaF levels providing baseline data, which was then normalised to control 3H-2-OG 
hydrolysis without presence of inhibitors and graphs were generated as % of control 
activity. 
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Figure 3.6 Effect of NaF concentration response on MAGL activity assessed 
using radiolabelled 2-OG as substrate in radioligand binding MAGL 
assay in homogenate, particulate and soluble fractions of rat brain 
tissue. Data were collected in triplicates and expressed the mean ± 
SEM of three individual experiments and expressed as % control of 
3H 2-OG hydrolysis. 
Data suggest there to be no significant MAGL inhibition by NaF at concetrations of 100 
µM to 3 mM, with modest, non-significant inhibitory effects at higher concentrations 
(figure 3.6). Interestingly, the highest concentration of NaF applied (100 mM) evoked an 
inhibition to 74% control MAGL activity response, whereas it has been reported in 
literature that the use of 25 mM NaF produces 10% control MAGL activity response 
(Somma-Delpero et al., 1995). Differences in the assays, such as their use of purified 
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MAGL on radiometricassay methods may well account for the difference in responses 
observed, nevertheless there is a large difference between these two results. 
3.2.6 HTS MAGL inhibitors in rat liver and brain 
As section 3.3.4 suggests rat brain is a good source of MAGL activity and the well 
known knowledge of the high levels of enzyme activity in the liver, we compared MAGL 
activity rates using the HTS methodology to see how inhibitor actions varied between the 
tissues and which one provided the highest levels of MAGL activity and hence able to 
display the best sensitivity to MAGL inhibitors. We extracted rat brain and liver tissue 
from three male Wistar rats (150-200 g), and tissue was prepared as in section 3.2. 
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Figure 3.7 Effects of potential MAGL inhibitors in liver and brain cytosolic 
fractions, with the use of 100 mM NaF, 1 pM MAFP, 10 pM ATFMK 
and 100 pM URB602. Data were collected in triplicates and expressed 
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as the mean f SEM from three individual experiments and expressed 
as % control of 4-NPA hydrolysis. 
Figure 3.7 clearly shows the liver to be more sensitive to MAGL inhibitors, compared 
with brain. There is a clear indication of non-specific esterase activity as treatment with 
inhibitor in the HTS assay is further reduced in the presence of NaF 
- 
in all cases. The 
use of NaF alongside other inhibitors in this graph represents the effects of NaF alone and 
not an additive or accumulative effect of the inhibitor and NaF compound together. As 
previously observed, rat brain MAGL shows no effects in the presence of MAFP, the 
reason for which is still unclear. We also see no effect of URB602 on MAGL activity in 
either tissues. In liver samples, there is a rank order of inhibition of: MAFP> NaF> 
ATMFK> URB602. 
Protein concentration and incubation time on HTS MAGL activity 
After determination of the liver as the best source of MAGL to use in this HTS MAGL 
assay method, we went further to see the effects of incubation time and protein 
concentration on MAGL activity, leading to further optimization of the assay. 
Tissue was prepared as in section 3.2. and diluted to either 1: 500 or 1: 100 of wet weight 
volume. MAFP was pre-incubated with enzyme for 15 minutes at 37 °C alongside a 
concentration curve of NaF, following this the assay was run as previously described. 
IC50 values were then calculated. 
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Figure 3.8 Effect of NaF as inhibitor of 4-NPA hydrolysis in liver cytosol fraction 
at different dilutions and time points. Data were collected in 
triplicates and expressed the mean ± SEM of three individual 
experiments. Data expressed as % control of 4-NPA hydrolysis, with 1 
pM MAFP. 
Liver tissue dilution 
1: 500 1: 1000 
5 min 
-3.16 -3.2 
15 min 
-2.99 -3.12 
Table 3.4 Log IC50 values for data in figure 3.8 conducted against NaF concentration response 
curve using liver cytosol fractions at two different dilutions and data extracted at 
two different time points. 
Results indicate IC50 values to be unaffected with increased protein concentration. Such 
" u'1: 500 
  +MAFP 
"Ur1 , 1000 
  +MAFP 
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marginal changes between time and protein concentration allows for choice towards low 
cost and efficiency. The use of low protein concentration enzyme source will provide 
more use out of each tissue sample preparation and a 15 minute incubation time will 
ensure all inhibitory effects of screened compounds to be observed, yet with large 
compound library screening, it provides the choice of an alternative 5 minute incubation 
time, to allow screening of more compounds, within the same time frame. Therefore a 15 
minute incubation time and 1: 1000 enzyme dilutions were chosen for further 
experiments, unless stated otherwise. 
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3.2.7 Validation of MAGL HTS assay 
To validate the assay, we assessed the effects of two MAGL inhibitors and a MAGL 
substrate, conducted as concentration response curves. 
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Figure 3.9 Concentration response curves of MAGL inhibitors on liver soluble 
fractions. Data collected in triplicates from three individual 
experiments and expressed as the expressed as % control t SEM of 4- 
NPA hydrolysis. 
MAFP AACOCF3 2-OG 
LOGEC50 
-6.7 -6.5 >-4 
Table 3.5 Log EC50 values for MAGL inhibitors on 4-NPA hydrolysis. 
The assay displays good sensitivity to inhibitors MAFP and AACOCF3 (figure 3.9), with 
comparable IC50 values to literature (Ahn et al., 2008), while 20G only evoked a 
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significant inhibition of NPA hydrolysis at 100 pM. In comparison, Ghafouri et at. 
(2004) observed an 109 IC50 value for 20G-mediated inhibition of rat brain MAGL 
activity of 4.9. 
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3.2.8 Application of MAGL HTS assay: HTS of compounds as potential MAGL 
inhibitors 
The following graphs show results of a high throughput screening of a large group of 
compounds. MAGL activity is indicated as % of control 4-NPA hydrolysis. For those 
samples exposed to MAFP, NPA hydrolysis was not different from tissues blanks. 
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Figure 3.10 MAGL HTS of cannabinoid ligands as potential inhibitors. 
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4-NPA hydrolysis (% MAFP-sensitive control) 
Cannabinoid ligands were screened as potential inhibitors at 100 µM, 
and their effect on MAGL hydrolysis of 250 pM 4-NPA. MAFP was 
used to determine MAFP-sensitive activity. Data were collected in 
single replicates (n=4). Data were analysed using one-way AVOVA 
(**P<0.01). 
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Figure 3.11 MAGL HTS of natural ligands as potential inhibitors. Cannabinoid 
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ligands were screened as potential inhibitors at 100 µM, and their 
effect on MAGL hydrolysis of 250 pM 4-NPA. MAFP was used to 
determine MAFP-sensitive activity. Data were collected in single 
replicates (n=4). Data were analysed using one-way AVOVA 
(**P<0.01). 
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Figure 3.12 MAGL HTS of NSAIDs as potential inhibitors. Cannabinoid ligands 
were screened as potential inhibitors at 100 µM, and their effect on 
MAGL hydrolysis of 250 pM 4-NPA. MAFP was used to determine 
MAFP-sensitive activity. Data were collected in single replicates 
(n=4). Data were analysed using one-way AVOVA (**P<0.01). 
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Figure 3.13 MAGL HTS of miscellaneous compounds as potential inhibitors. 
Cannabinoid ligands were screened as potential inhibitors at 100 µM, 
and their effect on MAGL hydrolysis of 250 pM 4-NPA. MAFP was 
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used to determine MAFP-sensitive activity. Data were collected in 
single replicates (n=4). Data were analysed using one-way AVOVA 
(**P<0.01). 
Figures 3.10-3.13 show the majority of compounds to be ineffective as inhibitors of NPA 
hydrolysis, either in the absence (pictured) or presence of MAFP (not shown). The non- 
psychoactive cannabinoid compound CBD, THCV and eCB AEA significantly inhibit 
MAGL activity, but to a much lesser degree compared to their effects on FAAH. THCV 
was the most effectiveMAGL inhibitor, closely followed by CBD (85 %), and AEA (83 
%), PPAHV and GW0742 also caused small, butsignificant inhibition. 
Of the natural ligands (figure 3.11) only the flavonoid 7-hydroxyflavanone caused a 
small (70 % control) yet significant MAGL inhibition. There was insufficient inhibition 
observed by the other natural compounds to allow generation of structure activity 
relationships. 
NSAIDs showed no inhibitory action on MAGL (figure 3.12), but a few miscellaneous 
compounds (figure 3.13) inhibited MAGL activity, namely carbenoxolone (86 %), 
ATRA and barbiturate (85 %). 
Overall, this HTS MAGL assay provides a good tool for the identification of potential 
MAGL inhibitors, in a rapid, inexpensive and facile manner. More conventional and 
MAGL specific assays would be required to investigate further potential `hits' identified 
from this method. 
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3.2.9 Z-Factor calculation 
The Z-factor, as previously mentioned in chapter 2, is a statistical analysis and measure 
of the size of effect within a given assay. It has been used in high throughput assays, to 
determine whether the response in an assay is large enough to warrant further attention, 
and provides an indication of the quality of the assay itself (Zhang et al., 1999). The final 
Z-factor value reflects both the assay signal dynamic range as well as the data variation 
associated with the signal measurements and therefore provides a through assay quality 
assessment. It is a value which clearly aids the process of assay optimization. 
Calculation 
Calculation of the Z-factor requires input of four parameters, the means and standard 
deviations of both positive (p) and negative (n) controls (4. ap and x,,. a). 
For the positive control values, the rate of reaction of OEA hydrolysis by FAAH in rat 
liver microsome fractions were used. For the negative control values of rates of reaction 
of OEA hydrolysis following FAAH incubation with its inhibitor URB597 were used. 
These values were obtained using the high throughput screening method as described in 
this chapter. 
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Given these values the Z-factor is defined by: 
Z-Factor =1- 3x ((Fp + ßn) / (xp 
- 
Xn) 
Interpretation 
Z-Factor Interpretaion 
1.0 Ideal. Z-Factor can never exceed 1. 
0.5-1.0 Excellent assay. 
0-0.5 Marginal assay. 
less than 
0 Too much overlap of positive and negative control for assay to be useful. 
HTS MAGL assay calculation 
positive negative 
control control 
(ODA) (URB) 
1.46 0.024 
1.33 0.024 
1.46 0.020 
1.30 0.023 
1.46 0.023 
1.36 0.024 
mean 1.393 0.023 
st dev 0.073 0.002 
Z- 
Factor 0.84 
Table 3.2 Z-factor value calculated using data from HTS FAAH inhibitor 
screening, with the use of 100 µM ODA and 5 µM URB597. 
The Z-factor score shows the HTS MAGL assay to be (at least from this parameter) an 
excellent tool in the screening identification of new potential MAGL inhibitors. Through 
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interpretation of the Z-factor values from both the FAAH (0.53) and MAGL (0.84) HTS 
assays, we can determine that the MAGL seems to be stronger, yet we know the FAAH 
to be more enzyme specific and that `hits' from the MAGL assay would require follow- 
up investigations of the compounds using more conventional assays. 
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3.4 Discussion 
4-nitrophenylacetate (NPA) has been identified as a useful substrate for MAG lipase 
using recombinant enzyme preparations, although hydrolysis by esterases other than 
MAG lipase in rat tissues limits its usefulness (Muccioli and Stella, 2008). In this 
chapter, we have identified that NPA can be utilised in a high-throughput screen for 
MAG lipase from native rat liver enzyme preparations, although there are significant 
limitations associated with it's use. It is likely that a better methodology would be to 
make use of human recombinant MAGL as the enzyme source for future inhibitor 
screening, thereby allowing some assurance of the validity of the assay. 
With the development of a selective MAGL inhibitor JZLI 84 (Long et al., 2009), a 
growing understanding of the physiological role of MAGL is beginning to emerge and 
will continue to provide information of its involvement in various pathological states. In 
turn, there will be an increasing need to identify potential inhibitors of MAGL which may 
alter its role in the presence of inhibitory ligands, especially endogenously active ones. 
Therefore such a simple, cheap and facile HTS assay will provide rapid screening of 
compounds of libraries as well as known compounds, to indicate possible inhibitors for 
further investigation. 
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Chapter 4: THE ROLE OF OEA IN FOOD INTAKE 
AND SATIETY IN THE MOUSE 
4.1 Introduction 
Phytocannabinoids and synthetic cannabinoids are appetite stimulants through activation 
of CB 1 receptors located in the CNS. Endocannabinoids (eCB) and endocannabinoid-like 
molecules (eCBL) can also activate CB 1 receptors to work in the same way (Guzman et 
al., 2004). Hence, drugs that can diminish eCB activity at CB 1 receptors (for example, 
rimonabant) provide good appetite suppression and show efficacy in the treatment of 
obesity and type-2 diabetes (Fu et al., 2005). OEA has been shown to lack binding 
affinity to CB1 receptors, which has led to further investigation into the role of 
endogenous OEA and its involvement in other receptor mechanism pathways. As with 
other eCB compounds and eCBL molecules, OEA is a naturally occurring lipid thought 
to be produced on demand. Its synthesis in the GI tract appears to be stimulated upon 
feeding (Fu et al., 2005), suggesting OEA may participate in regulating satiety. 
Investigation into OEA's locus of action found that feeding stimulated OEA mobilisation 
in proximal areas of the small intestine. It was found not to be mobilised in other areas of 
the gastrointestinal tract, CNS or other peripheral tissues. This mobilisation local of OEA 
was accompanied by enhanced accumulation of OEA-generating NAPE, increased 
activity and expression of OEA-synthesising NAPE-PLD, decreased activity and 
expression of OEA-degrading FAAH (Fu et al., 2007). 
As described in section 1.7 exogenous administration of OEA (20 mg. kg, i. p. ) in rats has 
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been shown to cause a dose-dependant delay in feeding onset of free-feeding animals, 
without altering meal size or post-meal intervals. OEA also delayed feeding onset in food 
deprived rats, and reduced meal size (Gaetani et al., 2003). The anorexic effects of OEA 
do not occur when directly injected into the brain but only when injected i. p (OEA #1), 
with actions being independent of appetite regulating hormone mechanisms (Proulx et al., 
2005), and requiring intact sensory fibres (Gaetani et al., 2003), further indicating a 
peripheral receptor target. One likely target would be through activation of receptors 
expressed in the walls of the small intestine sending signals through vagal sensory 
neurons directly to the hypothalamus to induce satiety (Fu et al., 2005). 
PPARa is a nuclear receptor reported to be highly expressed in the small intestine in 
close proximity to the vagal sensory neurone and is known to be involved in the handling 
of fats in the blood-and liver (Fu et al., 2005). PPARa agonists, such as fenofibrate, lower 
triglyceride levels in blood and also have beneficial effects on cholesterol, yet they have 
not been reported to affect appetite. OEA exhibits a nanomolar-range binding affinity for 
PPARa, this may therefore account for the effects of OEA on appetite (Fu et al., 2003). 
OEA, in vivo and in vitro, behaves as a PPARa agonist by decreasing natural lipid 
content in hepatocytes by enhancing fatty acid oxidation, reducing serum cholesterol and 
reducing triglyceride levels (Guzman et al., 2004) as well as reducing food intake, effects 
that are not observed in PPARa"'" rats (Fu et al., 2003). 
An alternative explanation for the role of OEA in the regulation of food intake may be 
through the entourage effect. This hypothesis suggests that OEA, as well as other eCBL 
molecules have indirect effects on CBI receptors by diverting the hydrolytic activity of 
FAAH, thereby leading to an accumulation of canonical eCB molecules (Mechoulam et 
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al., 1997), potentially activating CB1 receptors. 
Given these alternatives, we have attempted to investigate the nature of OEA influences 
on feeding behaviour, making use of pharmacological and genetic models, as well as 
analytical methods, to determine the locus of action of OEA. 
4.2 OEA dose response and locomotor activity effects in mice 
4.2.1 Introduction 
Cannabinoid compounds are known- to produce unwanted physiological responses, such 
as the psychotropic effects of cannabis, alterations in cognition and memory, sedation and 
immobility. These are thought to be largely mediated by the CB1, and to a lesser extent 
CB2 receptors (Sun et at., 2007) (Howlett, 1995). The eCBL compounds, such as OEA, 
are structurally related to cannabinoids, yet have been described not to activate CB 
receptors (Fu et al., 2003) (Fu et al., 2005). There is still much to be learnt of the receptor 
targets and subsequent physiological effects exerted by the eCBL compounds. 
In the literature, previous doses of OEA administered intraperitoneally to mice and rats 
have ranged from 10-15 mg/kg (Thabuis et al., 2008). Here we investigate the effect of a 
range of doses of OEA on sedation, locomotor activity and other behavioural effects prior 
to investigating the effects of OEA on food intake. 
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4.2.2 Method 
Eight C57b16 male adult mice were given i. p injections of 1,10 and 20 mg/kg OEA and 
vehicle (5% Tween 80,5% PEG 300,90% sterile saline), on a7 day cycle. Mice were on 
a 12 hour dark: light cycle and were dosed at 4 hours into the dark phase. They were then 
placed in individual LMA Perspex boxes and the distance moved by each mouse was 
electronically measured electronically for 60 minutes. 
LMA equipment 
Each mouse was placed into a 30 cm x 60 cm clear Perspex box with a solid coloured 
digitising base. Above each box was a video camera linked (live) to a computer to track 
the movement of each mouse. Tracking of the animal was achieved by the computer 
calculating the difference between two sequential pictures, taken 10 
- 
15 frames per 
second. The differences add up to provide the total distance moved by the mouse. 
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4.2.3 Results 
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Figure 4.1 Dose dependant effects of OEA on locomotor activity. Eight C57b16 adult male mice, 
counted from point of injection in 5 minute time bins up to 60 minutes post- 
injection. Data were analysed using two-way ANOVA with Bonferroni's post-hoc 
test. 
There was a small, non-significant reduction in activity evoked by OEA compared with 
vehicle treatment at early time points following injection. For all treatments, including 
vehicle, there was a decline in locomotor activity following injection. 
The mice achieved a steady state level of activity 45 minutes post-injection. 
. 
4.2.4 Discussion 
The locomotor activity observed post-injection with vehicle and 1 mg/kg OEA is 
probably associated with the disturbance and discomfort associated with the injection. 
The lower levels of locomotor activity observed at doses of 5 and 10 mg/kg OEA suggest 
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that these doses are not painful (Wang, 2005 13076 /id), and in fact may actually evoke 
analgesia or sedation. All sedative effects of cannabinoids previously described have 
involved CB receptor-mediated mechanisms (Howlett et al 1995). There is no evidence 
in the literature highlighting any sedative effects caused by eCB or eCBL compounds 
through non-CB receptor-mediated mechanism pathways. 
There was no significant difference between the doses of OEA in observed behaviour and 
locomotor activity. These doses were, therefore, investigated for effects on the reduction 
of food intake 
. 
4.3 Dose dependant effects of OEA on food intake 
4.3.1 Introduction 
OEA (10 mg/kg, i. p. ) was observed to significantly reduce food intake over 0-12 hours in 
PPARa+/+ mice and not in PPARa4" mice (Lo Verme et al., 2005). It has been suggested 
that OEA's effects on feeding are short lived suggesting OEA is rapidly eliminated after 
systemic administration (Piomelli, 2003). Measured OEA plasma levels in free-feeding 
rats, following a single acute i. p. injection of 5 mg/kg OEA showed OEA concentrations 
to sharply increase and return back to baseline levels within 60 minutes post-injection, 
where there were significant differences between test and control values for up to 30 
minutes but not 60 minutes (Piomelli, 2003). This reflects the rapid distribution and 
catabolism of OEA by eCBL hydrolysing enzymes. OEA has also been described to show 
a dose dependant relationship (5,10,20 mg/kg) with latency of feeding, with no change 
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in meal sizes or post meal intervals, as well as a reduction in meal frequency with the 
higher doses of OEA (10 and 20 mg/kg) (Lo Verme et al., 2005). 
In this next section, I have examined the effects of a range of OEA doses on parameters 
of food intake, latency of feeding, post meal intervals, activity, oxygen consumption and 
respiratory quotient. 
4.3.2 Methods 
Animals 
Experimental animals were obtained from a colony of C57b16 strain mice, maintained at 
the University of Nottingham BMSU, Medical School. They were housed in individual 
cages under controlled temperature (21 °C) and light (12 hr light, 12 hr dark cycle; lights 
off at 16: 00). All animals had ad libitum access to food intake and water. All animal 
procedures were approved by the University of Nottingham Local Ethical Review 
Committee and were carried out in accordance with the Animals Scientific Procedures 
Act (UK) 1986. 
CLAMS: OxyMax comprehensive lab animal monitoring system 
This is a metabolic closed-circuit metabolic system consisting of eight calorimetric 
chambers capable of simultaneously monitoring eight mice individually. It is able to 
measure, non-invasively, several physiological and behavioural parameters. This study 
focussed on total feeding, feeding bouts, total activity counts, oxygen consumption, 
carbon dioxide consumption and hence respiratory quotients. These parameter 
measurements are linked to automated computerised recordings using OxyMax software 
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collecting recordings every 6-8 minutes. All measurements were taken at an ambient 
temperature of 21-22°C. 
Picture 1: This picture displays the CLAMS setup as used in the following experiments described in 
this chapter. There are eight Perspex boxes all in a closed metabolic measurement 
system. Each animal setup is completely sealed so all metabolic gases, waste and food 
intake are accurately measured through computerised calibration systems. Data on those 
parameters as well as all movement and activity are electronically transferred and 
available for analysis. 
Oxygen consumption (V02): 
V02 for each chamber is calibrated to the relative change in pressure following the 
removal of carbon dioxide and water from the system using soda lime. VO2 was 
measured as ml 02 per minute per kilogram metabolic body weight (ml/min/kg0.75). The 
system was operated with an air intake of 0.6 litres/min per chamber, and an extracted 
outflow of 0.4 litres/min. 
Respiratory Quotient (RQ) 
RQ was calculated from the ratios of measured oxygen consumption and the amount of 
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carbon dioxide removed from the closed-circuit system using soda lime. 
Total activity 
Infra-red lasers crossing the Y, X and Z axis allow monitoring of a complete range of 
movement by the mouse within the chamber, including running, rearing and sleeping. 
Activity was recorded when two or more consecutive infrared beams positioned 
approximately 2 cm apart were broken. Total activity counts were assessed over the 0-24 
hour period post injection. 
Feeding 
Each chamber holds a food hopper positioned in the middle of the chamber containing 
ground chow and linked to a digital scale with information automated fed into OxyMax 
computer software, where all removal of food was recorded. Parameters measured 
included total food intake, meal frequency and duration of feeding bouts and food 
consumption per bout. A bout of food intake (meal) was defined as an intake of greater 
than 0.02 g. Water was provided by dropper bottles, but water intake was not recorded. 
Picture 2: The above picture shows the food hopper which is independently filled and put in place 
on the base containing a digital scale, measuring the food hopper contents, with the 
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Perspex metabolic box sealed and fitted over the food hopper with it entering inside the 
box providing a small space allowing for the mice to scurry food out of the hopper. Food 
which the mice do not eat can only fall back on the food hopper and nowhere inside the 
Perspex box, giving a constantly accurate measure of the direct food intake of the mouse 
in that box. 
Experimental procedure 
Eight adult male mice were separated into four treatment groups, where all mice received 
all treatments over a period of four weeks (allowing for a drug washout period) in a 
pseudo random order, allowing each mouse to act as its own control. The mice were 
placed into individual CLAMS chambers for a 24 hour habituation period pre-dosing. 
They were then injected (10 RUg, i. p) with their respective doses at the onset of the dark 
phase and then placed back into their respective CLAMS chambers and all parameters 
were measured for a further 24 hour period. Vehicle was 5% Tween 80,5% PEG 300, 
90% sterile saline. 
Group I Group 2 Group 3 Grou 4 
mouse 1 2 3 4 5 6 7 8 
Week 1 Vehicle OEA (1 m) OEA (5 mg/kg) OEA (10 m g) 
Week 2 OEA (10 mg/kg) Vehicle OEA (1 m) OEA (5 mg/kg) 
Week 3 OEA 5m) OEA (10 mg/kg) Vehicle OEA (1 mg/kg) 
Week 4 OEA (1 m) OEA (5 mg/kg) OEA (10 mg/kg) Vehicle 
Table 4.1 The experimental dosing plan of all eight mice in a pseudo-random order with 
varying doses of OEA over four weeks. 
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Statistical analysis 
Measurement of food intake, activity, V02 and RQ 
The doses of OEA were compared with vehicle treatments using repeated measures 
ANOVA by a Dunnett's procedure for post-hoc comparisons between groups of 
treatments. 
All data shown in this section were collected from eight individual animals, unless stated 
otherwise. 
4.3.3 Results 
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Figure 4.2 Cumulative food intake for 0-24 hours post-injection. Mice treated with 1,5,10 
mg/kg OEA and vehicle (n=8). The bars below the graph indicate 12 hour dark and 
light phase. 0-24 hour data were analysed comparing OEA treated against vehicle, 
using two-way ANOVA with Bonferroni's post-hoc test. 
128 
vs Y 
E 
E 
N 
11 
Figure4.3 
M 
r 
Q 
Time Bins (hr) 
Figure 4.4 
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Oxygen consumption of mice 0-24 hours post-injection. Mice treated with 1,5,10 
mg/kg OEA and vehicle (n=8). Data were grouped into 6 time bins and were analysed 
using two-way ANOVA with Dunnett's Post-hoc test. 
Vehicle 
M1 mg/kg 
M5 mg/kg 
- 10 mg/kg 
Locomotor activity 0-24 hours post-injection. Activity measured in eight mice (n=8) 
in 6 time bins over 0-24 hour period. Data were analysed using two-way ANOVA 
with Dunnett's post-hoc test. 
129 
3 
.I2 
ö2 
dl 
c 
1 
Figure 4.5 
vehicle 
M1 mg/kg 
M5 mg/kg 
M 10 mg/kg 
0-1 1-2 2-4 4-6 6-8 
time (hr) 
Feeding bouts in eight mice (n=8) over the 24 hours following injection. Data 
were analysed using one-way ANOVA with Dunnett's post-hoc test. 
OEA 
Vehicle I mg/kg 5 mg/kg 10 mg/kg 
Respiratory Quotient 0.93 t 0.. 01 0.91 f 0.01 0.92 t 0.01 0.94 t 0.01 (mg/kg/hr) 
Locomotor Activity 235 ± 59 302 f 48 289 t 41 260 t 33 (no. of beam breaks) 
Post meal interval 25 ±4 27 ±4 29 ±2 33 ±9 (min) 
Latency of first feed 69 ± 11 33 ±6 71 ± 17 104 ± 24 (min) 
Table 4.2 Data collected from eight mice (n=8) 0-24 hours post-injection. RQ and total 
activity were analysed using two-way ANOVA whereas post meal interval and 
latency of first feed were analysed using one way ANOVA; both were followed by 
Dunnett's post hoc test. 
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Food intake for the first hour following injection, in eight mice (n=8). Data were 
analysed using one-way repeated measures ANOVA. 
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Oxygen consumption for the first hour post-injection, in eight mice (n=8). Data 
were analysed using two-way ANOVA with Bonferroni post-hoc test. 
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Dose (OEA) 
OEA 
Vehicle 1 mg/kg 5 mg/kg 10 mg/kg 
Respiratory Quotient 
0.80 t 0.01 0.80 t 0.01 0.79 t 0.01 0.78 t 0.01 (mg/kg/hr) 
Locomotor Activity 
237 f 25 223 t 26 206 t 19 266 t 36 (no. of beam breaks) 
Table 4.3 Data collected from mice 0-1 hour post-injection, in eight mice (n=8). RQ and locomotor 
activity were analysed using two-way ANOVA with Dunnett's post hoc test. 
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Cumulative food intake for the first 5 hours post injection, in eight mice (n=8). 
Data were analysed using two-way ANOVA with Bonferroni's post-hoc test 
(**P<0.01). 
OEA significantly reduced food intake at doses of 5 mg/kg and 10 mg/kg, in the first 
hour (figure 4.6) following administration compared with vehicle treated animals 
(P<0.01 and P<0.05 respectively). This coincided with an acute reduction in V02 at both 
doses (figure 4.7), where the dose of 5 mg/kg evoked a significant reduction at 18 
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minutes post injection (P<0.05) and 10 mg/kg sustained this significant reduction up to 
27 minutes (P<0.05) The respiratory quotient did not change at either dose (table 4.3), 
compared with vehicle, nor did activity within the first hour post-injection. Latency of 
feeding onset (table 4.2) was not affected at either of the lower doses (1,5 mg/kg OEA) 
although there was an increase in time to the first feed with 10 mg/kg OEA, albeit non- 
significant. Post meal interval (table 4.2) showed a trend of increase with all doses 
compared with vehicle but again the interval times were non-significant. 
The reduction in cumulative food intake was maintained up to 5 hours post-injection 
(figure 4.8) with the highest dose of OEA (10 mg/kg; P<0.01) yet 5 mg/kg OEA did not 
maintain its significant reduction, indicating a transient effect of OEA on food intake. 
Results up to 24 hours post-injection (figure 4.2) show a significant reduction in food 
intake with 5 mg/kg, compared with vehicle (P<0.05), but this was not shown with the 
higher dose of 10 mg/kg. There were no significant changes observed in V02, locomotor 
activity or RQ at the 24 hour point (figure 4.3 and table 4.2). 
4.3.4 Discussion 
OEA appears to act as an anorexic agent at doses of 5 and 10 mg/kg (i. p. ) within the first 
hour of administration although the results show fluctuations in the levels of significance 
achieved between 1,5 and 24 hour time points (figures 4.2 and 4.8). 
OEA at 5 mg/kg reduced food intake more significantly than 10 mg/kg with effects 
observed only up to one hour post-injection. 10 mg/kg OEA's effects lasted up to 5 
hours. At 24 hours post-injection, OEA at 5 mg/kg and not 10 mg/kg was able to 
significantly reduce food intake, compared with vehicle. 
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Despite the higher level of significant reduction in food intake observed with 5 mg/kg 
OEA compared with 10 mg/kg, in the first hour post-injection (figure 4.2), there was not 
much difference in levels of food intake between both doses. Results suggest a dose of 10 
mg/kg OEA to be more effective in the reduction of food intake as it maintained its 
significant reduction up to 5 hours post-injection (figure 4.8). 
These results support literature that suggests OEA's actions to be transient due to its rapid 
catabolism by eCBL hydrolysing enzymes (Rodriguez de Fonseca et al., 2001). 
Mice were injected at the onset of the dark phase to ensure regular feeding patterns, 
where food intake is higher in the dark phase than the light. 
The level of significant reduction in food intake achieved by 5 mg/kg OEA and not 10 
mg/kg at 24 hours post-injection (figure 4.2), may be due to compensatory effects in the 
reduction of food intake up to the 5 hours point with the dose of 5 mg/kg (figure 4.8), 
which may have caused an overall increase (above significance) at the 24 hour point. 
No significant change was observed in parameters of V02, locomotor activity and RQ at 
24 hours post injection (figure 4.3 and table 4.2), suggesting the effects of OEA are 
diminished by this time point, presumably due to its catabolism. The only significant 
effect we observed as a result of OEA administration is in the acute reduction of V02 at 
18 and 27 minutes following injection (figure 4.3). As all other measured parameters 
showed no change at this time point compared with vehicle values, it is difficult to 
determine the mechanism of action that has caused this acute reduction in V02. OEA 
showed no change in RQ or locomotor activity throughout the 24 hours following 
injection (table 4.2) alongside no significant change in latency of feeding onset and 
number of feeds (table 4.2), strongly suggesting that the OEA-evoked response on food 
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intake is not a result of a change in the animals basal metabolic rate, but supports a 
mechanism involving direct signalling to the satiety centre resulting in the reductions of 
food intake. 
Previous studies have shown OEA levels to decrease in rats during food deprivation, and 
increase during re-feeding (Rodriguez de Fonseca et al., 2001). Yet the presence of OEA 
also causes changes in levels of the expression of its pre-cursor and the activity of its 
synthesising and metabolising enzymes, orchestrating a rapid response. We may therefore 
expect, when administered exogenously, the body to utilise OEA and metabolise it 
rapidly. 
The same group (Rodriguez de Fonseca et al., 2001) found endogenous levels of OEA to 
localise largely in proximal areas of the small intestine, suggesting a gastrointestinal 
locus of action. This led us further to investigate the possibility of a peripheral 
mechanism mediating OEA's effect. 
4.4 The role of OEA and PPARa receptor on energy balance and 
metabolism 
4.4.1 Introduction 
The actions of OEA on food intake have not been fully characterised. It is thought to act 
through various peripheral receptors located in the small intestine, one of which is the 
nuclear receptor PPARa, another is the recently de-orphanised GPCR named GPR119 
(Overton et al., 2006) as well as the vanilloid receptor TRPV1 (Ahern, 2003). OEA's 
peripheral activity has been shown to decrease food intake and have an action on satiety. 
Given the multiple potential mediators of OEA-evoked changes in feeding behaviours, 
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the local availability of PPARa knockout mice and interest in these receptors led us to 
investigate the role of a key mediator PPARa using pharmacological and, later, genetic 
means. 
The overall aim of this investigation was to understand the role of OEA in regulating 
feeding behaviour and to determine the involvement of this peripheral receptor to the 
effects observed on satiety. 
4.4.2 Method 
Given the results on food intake shown with doses of OEA in the previous study, we have 
administered OEA at a dose of 10 mg/kg, alone or alongside fenofibrate at a dose of 20 
mg/kg (equal to the maximum recommended human dose). 
Experimental procedure 
The same experimental procedure was applied as described in section 3.3.2. 
Group I Group 2 Group 3 Group 4 
Mouse -00. 1 2 3 4 5 6 7 S 
Week 1 Vehicle OEA (10 mg/kg) Fenofibrate 
OEA(10mg/kg) + 
(20 mg/kg) Fenofibrate (20 m 
OEA (10 mg/kg) 
Week 2 + Fenofibrate Vehicle OEA (10 mg/kg) Fenofibrate (20 mg/kg) 
(20 mg/kg) 
OEA (10 mg/kg) 
Week 3 Fenofibrate + Fenofibrate Vehicle OEA (10 mg/kg) (20 mg/kg) (20mg/kg) 
OEA (10 mg/kg) 
Week 4 OEA (10 mfig) Fenofibrate (20 mg/kg) + Fenofibrate 
Vehicle 
(20 mg/kg) 
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Table 4.4 Experimental dosing plan. Eight mice were treated in a pseudo-random order 
with treatment of Vehicle, OEA (10 mgtkg), fenofibrate (20 mglkg) and dual 
administration of both OEA and fenofibrate, over a four week period. 
137 
138 
4.4.3 Results 
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Figure 4.9 Cumulative food intake for mice for 24 hours post-injection. All experiments 
shown in this section have n=8 of data. The bars below the graph indicate 12 hour 
dark and light phase. 0-24 hour data were analysed comparing all treatments 
against vehicle, using one-way ANOVA with Dunnett's post-hoc test. 
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Figure 4.10 Oxygen consumption of mice for 24 hours post-injection. Data were analysed using 
one-way ANOVA with Dunnett's post-hoc test. 
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Figure 4.11 Total activity counts, in time bins from 0-24 hours post-injection. Data were analysed 
using complete activity counts measured at 24 hours post injection using one-way 
ANOVA with Dunnett's post-hoc test. 
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Figure 4.12 Number of feeds in mice for 24 hours post-injection. No. of feeds measured in time 
bins (hr). Data were analysed using one-way ANOVA with Dunnett's post-hoc 
test. 
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Figure 4.13 Total food intake for the first hour post-injection. Data were analysed using one-way 
repeated measures ANOVA, with Dunnetts' post-hoc test. 
Vehicle 
OEA 
10 mg/kg 
Fenofibrate 
20 mg/kg 
OEA + 
Fenofibrate 
Respiratory 
Quotient 0.90 + 
(mg/kg/hr) 0.95 ± 0.. 0l 0.92 ± 0.01 0.92 ± 0.01 0.01 ** 
Latency of first 
feed 
(min) 24±4 68±20 78±5 68±37 
Table 4.5 Data collected from mice 0-24 hour post-injection. RQ and latency of first feed were 
analysed using one-way ANOVA with Dunnett's post hoc test. 
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Figure 4.14 Cumulative food intake in mice for the first 5 hours post-injection. Data were 
analysed using one-way ANOVA with Dunnett's post-hoc test. 
OEA Fenofibrate OEA + 
Vehicle 10 mg/kg 20 mg/kg Fenofibrate 
No. of feeds 
(>0.06g) 21±2 15±2 21 ±1 10±3 
Table 4.6 
E1 
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Figure 4.15 
Data collected from mice 0-5 hour post-injection. No. of feeds were analysed 
using one-way ANOVA with Dunnett's post hoc test. 
60 Aoi , ý0 ry'1 Nlb lb OA ,0 
Time (mins) 
e 
Oxygen consumption from an hour pre-injection to 60 min post- injection. Data 
were analysed using Two-way ANOVA with Bonferroni's post-hoc test (*P<0.05). 
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vehicle 
OEA 
s Fenofibrate 
Vehicle 
OEA 
10 mgtkg 
Fenofibrate 
20 mgfkg 
OEA + 
Fenofibrate 
Respiratory 
Quotient 
(mg/kg/hr) 0.83 t 0.01 0.83 ± 0.01 0.83 ± 0.01 0.80 ± 0.01 
Locomotor Activity 
(no. of beam 
breaks) 411 t 35 271 ± 32* 388 ± 34 234 ± 29** 
Table 4.7 Data collected from mice 0-1 hour post-injection. No. of feeds were analysed using 
one-way ANOVA with Dunnett's post hoc test. 
OEA significantly decreased food intake 0-1 hours post injection (figure 4.13) (vehicle 
0.19 ± 0.02, OEA 0.075 ± 0.02; P<0.05). Fenofibrate, in comparison, had a marginal 
reduction (0.10 ± 0.04 g), although administration of the two compounds together evoked 
a significant reduction in food intake (0.06 ± 0.03 g; P<0.01). The effects of OEA and 
fenofibrate were lost after 2 hours, indicating a short acting response or rapid 
metabolism. In contrast, however administration of both agents simultaneously 
significantly maintained this reduction in food intake for up to 5 hours post-injection 
(figure 4.15), compared with vehicle (P<0.01). Combined administration of OEA and 
fenofibrate suppressed food intake over 0-24 hours post injection (figure 4.9) (vehicle 
6.94 ± 1.07; dual 4.02 ± 0.46 g; P<0.05), when neither OEA nor fenofibrate had any 
significant effect in the response at 0-24 hours when administered alone. Alongside this 
we observed a trend of increased latency of feeding onset with all treatments (table 4.5), 
in the order of fenofibrate, OEA and combined administration, compared with vehicle, 
albeit non-significant. 
The decrease of food intake with both OEA and the combined administration of OEA and 
fenofibrate was associated with an acute reduction in oxygen consumption 0-1 hour post 
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injection (figure 4.15), where OEA elicited an acute significant reduction in V02 (1369 
± 108 mg kg-1 hr 1; P<0.05) 36 minutes post-injection, where combined administration 
showed a significant reduction (1277 ± 143; P<0.05), compared with vehicle, at both 27 
and 36 minutes post-injection, which was rapidly reversed, whereas fenofibrate alone had 
no effect on this parameter. There was no significant change over the 24 hour period 
following administration in V02 (figure 4.10). 
Alongside this the respiratory quotient remained unaffected by any treatment within the 
first hour post injection (table 4.7), yet significant reduction of RQ was seen with dual 
administration, at 24 hours post-injection (table 4.5). No hyperactivity or sedation was 
evident, but decreased activity was observed in the first hour (table 4.7), in the order of 
fenofibrate, OEA and dual administration, where OEA and combined OEA and 
fenofibrate administration caused a significant reduction (P<0.05 and P<0.01 
respectively), compared to vehicle. Mice treated with OEA lost this effect on activity but 
over the 0-24 hour period activity (table 4.5) remained significantly reduced, when 
compared with vehicle, for mice treated with both OEA and fenofibrate together. 
4.4.4 Discussion 
One potential interpretation of these results is that OEA is acting at PPARa nuclear 
receptors, located in the walls of the small intestine. Pharmacodynamically, the 
maintenance in the reduction of food intake suggests potentiation of the effect of OEA 
when administered with fenofibrate, although the time profile of OEA indicates the 
possibility that this response is an additive effect, with OEA being involved in a different 
peripheral mechanism adding to the effects of fenofibrate at PPARa on food intake. 
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Various receptors have been investigated for their affinity for eCBLs. OEA has been 
reported to be an endogenous agonist at GPR119, whose physiological response is yet 
undetermined, as well as the vanilloid receptor TRPV 1. Anorexic effects mediated by 
these receptors have not been reported in literature and their possible involvement with 
OEA in the reduction of food intake would need to be further investigated (Wang et al., 
2005) (Overton et al., 2006). Pharmacokinetically, it can be hypothesised that fenofibrate 
may be able to inhibit OEA metabolism or displace it from a non-functional binding site, 
therefore increasing its bioavailability. 
The acute reduction in V02 observed with OEA, but not by fenofibrate, supports acute 
effects on V02 observed in the previous chapter with OEA alone, yet the mechanism by 
which this occurs is still undetermined. 
The reduced RQ may be evidence for an additive effect of OEA and fenofibrate mediated 
response in direct activation of PPARa (for example), as neither compound alone induced 
a reduction of RQ. This may be a result of high potency binding and activation of the 
PPARoc receptor by both OEA and fenofibrate, both of which are able to cause changes 
in transcriptional activity (Sun et al., 2006) and drive the mice more towards protein 
metabolism than carbohydrate as seen with the other treatments, this may also be possible 
in the time of 24 hours post-injection. Dual administration also showed a significant 
reduction in activity compared to vehicle between 2-6 hours post-injection, again 
indicating a response to mechanisms involving both compounds as this was not observed 
though administration of either compound alone. 
Results so far suggest a different time course in the effects of both compounds when 
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administered individually, yet the additive effect observed through dual administration of 
both compounds indicate an additive effect towards the overall effects on satiety. The 
different effects of OEA and fenofibrate administration suggest distinct mechanisms of 
action or differences in their pharmacokinetic profiles in vivo, while the extended 
duration of action of OEA with fenofibrate co-administration suggests a potentially novel 
indirect effect of PPARa receptors on food intake. 
4.5 The role of OEA on energy balance and metabolism independent of 
PPARa 
4.5.1 Introduction 
GW6471 has only been used once previously in vivo, in a recent local study in which it 
was administered through an intraplantar injection at a dose of 0.12 mg/kg for the 
investigation of local effects. Informal discussions with GSK personnel suggested that the 
compound had a poor bioavailability profile in vivo. The dose of GW6471 chosen (20 
mg/kg) was based on previous in vitro assays, drawing parallels with effects of PPARa 
agonists. 
4.5.2 Method 
GW6471 has only been used once previously in vivo, administered through an 
interplantar injection at a dose of (0.12 mg/kg) for the investigation of local effects and 
has been reported to have a poor absorption profile in vivo. The dose of GW6471 was 
therefore based on previously used in vitro assays which led to a dose selection of 20 
mg/kg for the investigation of the effects of GW6471 as a PPARa antagonist in vivo. 
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Experimental procedure 
-º 
mouse 
Week 1 
Week 2 
Week 3 
Week 4 
The same experimental procedure was applied as described in section 3.3.2. 
Group 1 Group 2 Group 3 Group 4 
1 2 3 4 5 6 7 8 
Vehicle OEA (10 mg/kg) GW6471 (20 mg/kg) OEA + GW6471 
OEA + GW6471 Vehicle OEA (10 mg/kg) GW6471 (20 mg/kg) 
GW6471 (20 mg/kg) OEA + GW6471 Vehicle OEA (10 mg/kg) 
OEA (10 mg/kg) GW6471 (20 mg/kg) OEA + GW6471 Vehicle 
Table 4.8 Experimental dosing plan. Eight mice treated in a pseudo-random order with 
treatment of Vehicle, OEA (10 mg/kg), GW6471 (20 mg/kg) and dual 
administration of both OEA and GW6471, over a four week period. 
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4.5.3 Results 
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Figure 4.16 Cumulative food intake for mice for 24 hours post-injection. All data are n=8 for 
this and all other results shown in this section. The bars below the graph indicate 
12 hour dark and light phase. Data were analysed comparing all treatments 
against vehicle, using two-way ANOVA with Dunnett's post-hoc test. 
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Figure 4.17 Oxygen consumption of mice for 24 hours post-injection. Data were analysed 
using one-way ANOVA with Dunnett's post-hoc test. 
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OEA GW6471 OEA + 
Vehicle 10 mg/kg 20 mg/kg GW6471 
Respiratory 
Quotient 
(mg/kg/hr) 0.96 f 0.. 01 0.94 ± 0.01 0.97 ± 0.01 0.93 t 0.01 * 
Locomotor Activity 
(no. of beam 
breaks) 291 f 43 234 ± 25 225 ± 26 261 ± 34 
Latency of first 
feed 
(min) 30±8 47±14 47±7 44±11 
Table 4.9 Data collected from mice 0-24 hours post-injection. RQ and total activity were 
analysed using two-way ANOVA whereas latency of first feed were analysed 
using one way ANOVA; both were followed by Dunnett's post hoc test. 
OEA GW6471 OEA + 
Vehicle 10 mg/kg 20 mg/kg GW6471 
No. of feeds 
(>0.06) 20±3 8±2 12±2 10±3 
Food Intake 
(g) 0.66±0.23 0.61 ± 0.22 0.62±0.21 0.60±0.23 
Table 4.10 Data collected from mice 0-5 hours post-injection. No. of feeds and food intake were 
analysed using two-way ANOVA with Dunnett's post hoc test. 
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Figure 4.20 Oxygen consumption from an hour pre-injection to 60 min post- Injection. Data were 
analysed using Two-way ANOVA with Bonferroni's post-hoc test (*p<0.05). 
;; 
Total food intake in mice for the first hour post-injection. Data were analysed using 
two-way repeated measures ANOVA, with Dunnetts' post-hoc test. 
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Vehicle 
OEA 
10 mg/kg 
GW6471 
20 mg/kg 
OEA + 
GW6471 
Respiratory 
Quotient 
(m r) 0.98±0.. 01 0.96±0.01 0.95±0.01 0.95±0.01 
Locomotor Activity 
(no. of beam 
breaks) 286 t 37 250 ± 34 209 ± 39 294 t 36 
Table 4.11 Data collected from mice 0-1 hours post-injection. No. of feeds and food intake 
were analysed using two-way ANOVA with Dunnett's post hoc test. 
Administration of OEA, GW6471 or combined administration of both compounds 
elicited a reduction in food intake in the first hour post-injection (OEA=P<0.01, 
GW6471 and dual administration =P<0.05). This significant reduction was lost with all 
treatments by 5 hours post-injection. At 24 hours post-injection cumulative food intake 
appeared reduced (not significantly), compared to vehicle, in the order of OEA>dual 
administration yet the PPARcc antagonist enhanced food intake compared to vehicle, 
albeit not significantly. There was a trend of increased latency of feeding onset in the 
order of OEA, GW6471 and dual administration of both compounds. 
GW6471 administration produced the highest reduction in activity in the first hour 
following administration although it was not significant. At 24 hours, combined 
administration caused a significant reduction in RQ (p<0.05) suggesting a switch 
towards protein metabolism in the mice, as observed in the previous chapter with 
combined OEA and fenofibrate administration (RQ=0.821). 
OEA showed the only trend of decrease in V02 following injection (at 30 minutes, albeit 
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non-significantly), and treatment with GW6471 alone significantly reduced V02 at 9 
minutes post-injection (p<0.05), but displayed a quick recovery as seen with OEA in 
previous in vivo experiments. All other compounds followed the profile displayed by 
vehicle treatment. There was no significant effect of any compound 24 hours post- 
injection on oxygen consumption. 
4.5.4 Discussion 
The PPARa antagonist GW6471 was employed to allow us to determine the involvement 
of PPARa receptor in the OEA-mediated effects on food intake. Due to the lack of in vivo 
use and knowledge of the pharmacokinetic profile of GW6471, GW6471 was 
administered alone to determine its behavioral effects in vivo. In our hands, GW6471 (20 
mg/kg) evoked a significant reduction in food intake in either the absence or presence of 
OEA. The precise mechanism for this is unclear, as is the involvement of PPARcz 
receptors. It should be noted, however, that a reduction in food intake could be induced 
by a non-specific feeling of malaise. If that were the case for GW6471 we would expect 
to see a reduction in locomotor activity, which was not present. Analysis of food intake 5 
hours post-injection showed no sustained significant reduction in food intake with 
GW647 1, indicating the effects of this compound, as well as OEA, to be transient. Figure 
4.16 shows food intake up to 24 hours post-injection and shows levels of food intake to 
be reduced the most by OEA treatment, and this effect is reduced with treatment of OEA 
with GW6471, indicating at least a partial contribution of PPARa. Further experiments 
would need to be conducted to determine whether a higher dose of GW6471 would 
inhibit the effects of OEA completely. Treatment with GW6471 alone showed a 
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reduction in food intake, compared to vehicle, suggesting tonic PPARa receptor 
activation with an endogenous ligand. This experiment is conducted with free-feeding 
animals and it is known that OEA is synthesized in response to feeding (Piomelli 2006). 
It is a distinct possibility that endogenous levels of OEA synthesized de novo may be 
acting at PPARa receptors to produce this tonic activation. 
All treatments showed trends of decreased RQ within the first hour post-injection, yet at 
24 hours combined administration alone showed a significant reduction in RQ, indicating 
a possible change to the metabolic rate of the animal. As seen in section 4.5.3, RQ was 
observed to decrease with combined administration of OEA and PPARa receptor agonist 
fenofibrate, indicating an involvement of OEA the change in basal metabolic rate. It was 
previously hypothesised that, as PPARa is a nuclear receptor, the change in RQ could be 
due to changes in transcriptional activity, yet this is unlikely now that the same effects 
have now been observed by OEA alongside a receptor antagonist. The contribution of 
GW6471 alone in this effect is therefore undetermined. 
OEA treatment displayed a trend similar to that seen in figures 4.14 and figure 4.7 on 
V02, but to a lesser (not significant) degree, yet GW6471 alone produced a sudden, 
transient reduction in V02 at 9 minutes post injection (p<0.05). The mechanism by which 
this effect occurs is still unknown. 
We show conflicting behavioural effects of GW6471 in vivo linked to feeding behaviours 
and the animals' metabolic profiles. The lack of knowledge and information on the 
bioavailability and pharmacokinetics of GW6471 makes it difficult to determine whether 
the doses given provide adequate concentrations of unchanged drug reaching systemic 
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circulation, leading to an optimal observational effect on feeding behavior by GW6471 
acting as an antagonist at PPARa receptors. Further investigation is required to determine 
the absolute bioavaiability of GW6471 in vivo by obtaining plasma drug concentrations 
over time. A further understanding of the bioavailability and pharmacokinetics of this 
compound would allow us to hypothesise the pharmacological mechanisms which may 
cause the transient increase in food intake when GW6471 is administered alone. Due to 
the known non-beneficial clinical effects of PPARa receptor blockade leading to 
myopathy and rhabdomyeolysis and yet the beneficial effects of PPARa agonism little 
research has been conducted using PPARa antagonists such as GW6471 as a 
pharmacological tool. Therefore we have little to no available in vivo data to provide- 
indications to dose related behavioral or metabolic effects in vivo. 
Analysis of data suggest OEA to have effects on food intake at the PPARa receptor as 
reduction of levels of food intake induced by OEA are reduced with the PPARa 
antagonist, yet the mechanism involved in the enhanced levels of food intake 24 hours 
post-injection with GW6471 are unclear and will need further investigation. Data support 
OEA's role to be a direct effect on satiety and not a change in metabolic state of the mice. 
4.6 OEA tissue levels following i. p. administration 
4.6.1 Introduction 
Investigations on the effects of endocannabinoid OEA (10 mgtkg) in mice have shown a 
significant reduction in food intake from the time of administration up to 5 hours, with a 
time of onset at 30 minutes post-dosing. Since the distribution of administered OEA post 
injection was unknown, we hypothesised that knowledge of tissue levels would allow 
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some insight into potential mechanisms of action. 
4.6.2 Method 
Experimental approach 
As 10 mg/kg OEA evoked a significant response in previous experiments, we used this 
dose, with a timepoint at the peak of the behavioural effect (30 minutes). A 60 minutes 
timepoint was also included to indicate turnover of eCBs in those tissues. Analysis of 
eCBs other than OEA will also give some insight as to whether its effects are indirect, for 
example by diverting FAAH activity and allowing the accumulation of AEA. 
Experimental design 
Mice were maintained on 12L: 12D, lights off 16: 00, on 04: 00. To comply with the 
previous experiments we administered OEA at the onset of the dark phase. Once the 
tissue had been dissected, it was weighed and frozen in liquid nitrogen before being 
placed in a collection tube and stored at 
-80°C until it was required to use as a LC- 
MS/MS sample to measure levels of OEA, PEA, AEA and 2-AG. 
18 adult males will be split into four groups. 
Endocannabinoid extraction method 
Dry glass homogenizing tubes, centrifuge tubes and glass pipettes were silanised by 
filling with 5% dichloromethyl silane in toluene and left for 30 minutes in a fume 
cupboard. They were then washed out once using toluene and twice with methanol and 
allowed to dry. 
Weighed tissue samples were placed in the homogenizing tubes, and kept on ice. 100 µL 
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d8 2-AG and/or 15 pL of d8 AEA was added to each homogenizing tube containing 
sample and vortexed. HPLC grade ethyl acetate/hexane were mixed to a 9: 1 ratio and 5 
mL was added to each homogenizing tube and left on ice for 15 minutes and then 
homogenized using a hand held pestle. 5 mL of de-ionised water was then added to each 
sample and each tissue re-homogenised. All of the sample was transferred from 
homogenizing tubes to plastic centrifuge tubes and vortexed. A further 5 mL of 9: 1 ethyl 
acetate/hexane was added to the homogenizing tubes as a washout for any remaining 
samples and left on ice. Centrifuge tubes were then centrifuged at 7000 rpm for 15 
minutes at 4°C. The supernatant layer was collected into silanised glass centrifuge tubes 
and plastic centrifuge tubes were re-filled with the remaining 5 mL ethyl acetate/hexane 
from each homogenizing tube. This was then centrifuged at 7000rpm for 15 minutes at 
4°C. This was repeated one further time. The combined supernatant layers in glass 
centrifuge tubes were placed in a rotary evaporator and centrifuged until the solvent was 
fully evaporated. 
Solid phase extraction (SPE) method 
Samples were reconstituted using 1 mL anhydrous chloroform in capped glass tubes, and 
placed on a vibrating shaker for 4 minutes. SPE cartridges were placed on a SPE rack 
with silanised glass collection tubes for the elute. Each cartridge was loaded with 
reconstituted sample using glass silanised pipettes. 
Each cartridge was then washed through in the following order: 
4x 1 ml wash- anhydrous chloroform 
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2x1ml elute A- anhydrous chloroform + 2% methanol 
4x 1 ml elute B- anhydrous chloroform + 2% methanol + 0.2% TEA 
4xlml elute C- anhydrous chloroform + 2% methanol + 0.05% TFA 
The pooled elution stages were then evaporated under nitrogen at 35 °C using a sample 
concentrator. Samples were then stored at -80 °C until analysis. 
Endocannabinoids were then quantified in samples using liquid chromatography tandem 
electrospray ionization mass spectrometry methods, run by Sarir Sarmad. 
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4.6.3 Endocannabinoids in the Liver 
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Figure 4.20 Endocannabinoid levels quantified in mouse liver tissues, following vehicle and OEA 
(10 mg/kg) treatment (i. p. ) and tissues collected 30 (a) and 60 (b) minutes post- 
injection (n=4). 
Levels of AEA and 2-AG in the mouse liver were similar and much lower than levels of 
OEA or PEA. 30 minutes following OEA administration, liver levels of OEA are 
significantly elevated, with no significant changes in PEA, AEA or 2-AG. OEA levels 
remain elevated at 60 minutes, with no significant changes in PEA, AEA or 2-AG. 
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4.6.4 Endocannabinoids in the ileum 
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Figure 4.21 Endocannabinoid levels quantified in mouse ileum tissues, following vehicle and 
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OEA (10 mg/kg) treatment (i. p. ) and tissues collected 30 minutes (a) and 60 minutes 
(b) post-injection (n=4). 
In the ileum, basal levels of AEA were similar to those in the liver. In contrast, levels of 
OEA and PEA were higher, while 2-AG levels were strikingly elevated compared to the 
liver. As in the liver, i. p. administartion of OEA resulted in a significant elevation of OEA 
levels in the ileum, without significant alterations in PEA, AEA or 2-AG. 
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4.6.5 Endocannabinoids in the duodenum 
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Figure 4.22 Endocannabinoid levels quantified in mouse duodenum tissues, following vehicle 
and OEA (10 mg/kg) treatment (i. p. ) and tissues collected 30 (a) and 60 (b) minutes 
post-injection (n=4). 
Basal levels of OEA in the duodenum were nearly twice that found in the liver and nearly 
three times lower than in the ileum. Basal levels show the amount of eCBL compounds 
measured to be 10-12-fold higher than levels of AEA and 2-AG. At 30 minutes OEA 
shows a 30-fold significant increase (P<0.01) compared to basal levels, with little change 
in PEA, AEA or 2-AG. eCB levels at 60 minutes post-injection show OEA to maintain 
this significant increase (P<0.01), again with no change in levels of PEA, AEA or 2-AG. 
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4.6.6 Endocannabinoids in the hypothalamus 
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Figure 4.23 Endocannabinoid levels quantified in mouse hypothalamus tissues, following vehicle 
and OEA (10 mg/kg) treatment (i. p. ) and tissues collected 30 (a) and 60 (b) minutes 
post-injection (n=4). 
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Basal levels show OEA and PEA to be 10-12 fold higher than that of AEA and 2-AG, 
with levels of PEA being slightly higher than that of OEA. There was no change in levels 
of all compounds at 30 and 60 minutes post-injection. 
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4.6.7 Endocannabinoids in the hippocampus 
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Figure 4.24 Endocannabinoid levels quantified in mouse hippocampus tissues, 
following vehicle and OEA (10 mg/kg) treatment (i. p. ) and tissues 
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collected 30 (a) and 60 (b) minutes post-injection (n=4). 
Basal levels of OEA were 7-8 fold higher than those of AEA and 2-AG, while basal 
levels of PEA were 8-9 fold higher also compared to the eCBs. Again, in this brain tissue, 
there was no change in levels measured at 30 and 60 minutes following injection with 
any of the compounds (figure 4.24). 
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4.6.8 OEA quantified levels 
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Figure 4.25 OEA levels quantified in mouse liver (a), ileum (b), duodenum (c), hypothalamus (d) 
and hippocampus (e) tissues, following vehicle and OEA treatment (10 mg/kg; i. p. ) 
and tissues collected at 30 and 60 minutes post-injection. Data were analysed using 
two-way ANOVA with Dunnett's post-hoc test (*p<0.05; **p<0.01). 
Figures 4.25 shows the changes in levels of OEA measured at both time points in each 
individual tissue. It is clear in the liver that OEA displays a trend of increase in OEA at 
both 30 and 60 minutes, albeit not significant. In the ileum however, OEA administration 
caused a significant increase at 30 minutes (P<0.01) which is slightly decreased, yet still 
significant, at 60 minutes (P<0.05). In the duodenum, there was a significant increase in 
OEA levels at 30 minutes (P<0.01) which was sustained up to the 60 minute point 
(P<0.01). Both brain tissues showed no significant change in levels of OEA at either 30 
or 60 minutes. 
4.6.9 Discussion 
OEA's actions on satiety are peripheral in their site of action and do not involve PEA, 
AEA or 2-AG. Tissues levels are regulated by FAAH, which makes a contribution to the 
reduction in eCB levels measured at 60 minutes compared to 30 minutes. It is clear that 
exogenously administered OEA reaches the liver, ileum and duodenum, but does not 
seem to reach central tissues (hippocampus and hypothalamus). Levels of OEA in the 
liver increase as a result of mobilization of exogenously administered OEA. We know 
(section 2.4.1) FAAH activity is at its highest in the liver and this may in turn explain 
high, rapid rates of OEA metabolism by its primary hydrolyzing enzyme FAAH reducing 
levels of OEA achieved in this tissue between the 30 and 60 minute time points, and 
overall, causing OEA to not reach a level of significant increase in the liver. 
The ileum has levels of FAAH activity lower than the liver, yet higher than measured in 
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the duodenum (Duncan et al., 2008). OEA administration shows significant increase of 
OEA in this tissue within the transient time frame OEA has previously displayed its 
actions on satiety. These data indicate the ileum as a site of OEA mobilization, indicating 
a locus of action, which is further supported by literature (Fu et al., 2003; Rodriguez de 
Fonseca et al. ). The lower levels of FAAH activity, compared to the liver may explain 
how OEA reached a significant levels (P<0.01) at 30 minutes, but the reduction in OEA 
from 30 to 60 minutes may still be explained by the level of FAAH activity present in 
this tissue. We would expect OEA hydrolysis to occur between 30 and 60 minutes 
causing the observed reduction in the significance (P<0.05) reached by OEA levels at 60 
minutes compared to 30 minutes. 
The duodenum shows high levels of OEA accumulation at 30 minutes following 
administration. Due to the lower levels of FAAH activity in the duodenum, the 
significant increase in levels of OEA is maintained up to 60 minutes post-administration. 
Overall, results indicate a gastrointestinal locus of action, which supports literature, 
where it has been found that endogenous levels of OEA, measured in fasted and feeding 
animals show mobilization in proximal areas of the small intestine (Fu et al., 2007; 
Piomelli et al., 2006). Piomelli's group have also reported lower levels of FAAH activity 
in proximal areas of the small intestine, in response to the increase of OEA levels 
initiated with onset of feeding. Further investigation of the effects of OEA on the 
expression and activity of OEA's synthesizing and hydrolyzing enzymes in various 
tissues may provide a better understanding of its role in the regulation of feeding. 
There are high levels of PPARoc expression in the walls of the small intestine, where 
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activation could potentially lead to signals being directly sent through the vagal sensory 
neurone (as describes in section 1.7), in response to PPARa activation, to the satiety 
centre, to induce satiety. 
Results do not support a central locus of action as exogenous OEA is not seen to alter 
OEA levels at either 30 or 60 minutes, directly in the hypothalamus itself or the larger 
brain section of the hippocampus. If OEA-mediated effects on food intake were centrally 
controlled and involved direct activation within the satiety centre, we would have 
expected levels in the hypothalamus to have been altered following OEA administration, 
yet this was not seen. We do not know if OEA can directly access the brain through the 
blood brain barrier, but OEA has been previously found not to induce its effects on food 
intake when injected directly into the brain, but only when administered i. p. in the 
periphery (Cravatt et al., 2007; Fu et al., 2007), again supporting the hypothesis that OEA 
exerts its effects through a peripheral, intestinal site of action. 
4.7 Investigation of the contribution of PPARa in OEA-evoked satiety 
responses using genetic animal models 
4.7.1 Introduction 
We have previously compared the effects of a known PPARa agonist, fenofibrate, 
PPARa antagonist GW647 1, and OEA in their effects mediated through PPARa receptor. 
Results indicated an additive effect of OEA, suggesting reduction in food intake is in part 
mediated by PPARa, yet another receptor mechanism may well account for part of the 
response measured. OEA has been found to reduce food intake in wild-type mice, but not 
in mice deficient in PPAR-a (PPAR-a; 4-) (Fu et al., 2005). Here we have used PPARa /- 
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mice to quantify the OEA-evoked response mediated by PPARa receptor. The overall 
- aim was to understand the role of PPAR-a in regulating feeding behaviour; this study will 
determine whether a functional PPAR-a is responsible for the individual effects of OEA, 
fenofibrate and GW6471 on food intake and satiety. 
4.7.2 Method 
Our previous experiments employing administration of OEA, fenofibrate and GW6471 
has allowed us to determine significant effects in food intake with doses of 10 mg/kg, 20 
mg/kg and 15 mg/kg respectively. We will therefore be administering these doses to 
PPAR-a-null mice to determine the involvement of PPAR-a receptor-dependent 
. 
mechanisms on regulation of food intake. 
Experimental procedure 
Eight PPARa '- mice and eight wild type mice (C57b16) were used as controls. The mice 
were split up into 4 knockout mice and 4 controls. Each treatment was given to one 
PPARa '" mouse and one control (according to table 4.13), following the same 
experimental procedure was applied as described in section 4.3.2. After mice were 
measured in the CLAMS for 48 hours, the experimental procedure was repeated with 
another set of 4 knockout and 4 control mice, to provide n=8 of knockouts versus control 
data. 
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Group 1 Group 2 Group 3 Group 4 
mouse 1(P) 1(C) 2(P) 2(C) 3(P) 3(C) 4(P) 4(C) 
Week 1 Vehicle OEA Fenofibrate GW6471 (10 mg/kg) (20 mg/kg) (15 mg/kg) 
Week 2 GW6471 Vehicle OEA Fenofibrate (15 mg/kg) (10 mg/kg) (20 mg/kg) 
Week 3 Fenofibrate GW6471 Vehicle OEA (20 mg/kg) (15 mg/kg) (10 mg/kg) 
Week 4 OEA Fenofibrate GW6471 Vehicle (10 mg/kg) (20 mg/kg) (15 mg/kg) 
Table 4.13 Experimental dosing plan of eight mice (4 x PPAR4' ((P)) and 4x control ((C)) (C57bl6)) in a pseudo-random order with treatment of Vehicle, OEA (10 mg/kg), 
GW6471 (20 mg/kg) and fenofibrate (20 mg/kg). following a CLAMS measurments 
session, the above table was repeated using mice 5-8 of both PPAR''' and controls. 
The experiment was run over a4 week period. 
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4.7.3 Results 
. -. vs 
,.. 
d Y 
cv 
c 
0 
0 
LL 
Time (hours) 
Figure 4.26 Cumulative food intake for control wild-type mice (C57bl6) for 24 hours post- 
injection (all experiments shown in this section have n=8 of data). The bars below 
the graph indicate 12 hour dark and light phase. 0-24 hour data were analysed 
comparing all treatments against vehicle, using one-way ANOVA with Dunnett's 
post-hoc test. 
174 
0123456789 101112131415161718192021222324 
0) 
a) Y 
ca 
c 
0 0 L 
Time (hours) 
Figure 4.27 Cumulative food intake for PPARoi " in eight mice for 24 hours post-injection. The 
bars below the graph indicate 12 hour dark and light phase. 0-24 hour data were 
analysed comparing all treatments against vehicle, using one-way ANOVA with 
Dunnett's post-hoc test. 
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Figure 4.28 Cumulative food intake for eight control wild-type mice (C57h16) for 5 hours post- 
injection. 0-5 hour data were analysed comparing all treatments against vehicle, 
using one-way ANOVA with Dunnett's post-hoc test (*p<0.05; **p<0.01; 
***p<0.001). 
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Figure 4.29 Cumulative food intake in eight PPARc '" mice for 5 hours post-injection. 0-5 hour 
data were analysed comparing all treatments against vehicle, using one-way 
ANOVA with Dunnett's post-hoc test. 
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Figure 4.30 Cumulative food intake in eight control wild-type mice (C57bl6) for 1 hour post- 
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injection. 0-1 hour data were analysed comparing all treatments against vehicle, 
using one-way ANOVA with Dunnett's post-hoc test. 
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Figure 4.31 Cumulative food intake in eight PPARo 4 mice for 1 hours post-injection. 0-1 hour 
data were analysed comparing all treatments against vehicle, using one-way 
ANOVA with Dunnett's post-hoc test (*p<0.05). 
wild-type mice Vehicle OEA Fenofibrate GW6471 
Respiratory 
Quotient 0.67 + 
(m /hr) 0.70 t 0.0 0.70 t 0.0 0.0*** 0.64 ± 0.0*** 
Locomotor Activity 
(no. of beam 
breaks) 241 t 19 239 ± 17 301 ± 24 168 f 13* 
PPARa knockouts 
Respiratory 
Quotient 
(mg/kg/hr) 0.69±0.0 0.70±0.0 0.69±0.0 0.69 0.0 
Locomotor Activity 
(no. of beam 
breaks) 201 f 13 204 ± 15 234 t 19 249 ± 16 
Table 4.14 Respiratory quotient and locomotor activity counts for 24 hours post-injection of 
wild-type mice (C57b16) and PPARd'" mice. Data were analysed using one-1way 
ANOVA with Dunnett's post hoc test (*p<0.05; ***p<0.001). 
177 
- 
\/chi0- ln 
NC 
0 
.E 
E 
Time(hours) 
Figure 4.32 Oxygen consumption in eight wild-type mice IC57bl61 for 24 hours post-injection. 0- 
24 hour data were analysed comparing all treatments against vehicle, using one-way 
ANOVA with Dunnett's post-hoc test. 
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Figure 4.33 Oxygen consumption in eight PPARoi - mice for 24 hours post-injection. 0-24 hour 
data were analysed comparing all treatments against vehicle, using one-way 
ANOVA with Dunnett's post-hoc test. 
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Figure 4.34 Oxygen consumption in eight wild-type mice (C57b16) for 1 hour post-injection. 0-1 
hour data were analysed comparing all treatments against vehicle, using one-way 
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ANOVA with Dunnett's post-hoc test (*p<0.05; **p<0.01). 
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Figure 4.35 Oxygen consumption in eight PPARoil- mice for 1 hour post-injection. 0-1 hour data 
were analysed comparing all treatments against vehicle, using one-way ANOVA 
with Dunnett's post-hoc test (*p<0.05; **p<0.01; ***p<0.001). 
wild-type mice Vehicle OEA Fenofibrate GW6471 
Respiratory 
Quotient 
(m r) 0.67±0.01 0.64±0.01 0.69±0.01 0.67±0.01 
Locomotor Activity 
(no. of beam 
breaks) 415 ± 80 243 ± 51 432 t 60 449 ± 87 
PPARa knockouts 
Respiratory 
Quotient 
(m r) 0.66±0.01 0.65±0.00 0.69±0.00 0.69±0.01 
Locomotor Activity 
(no. of beam 
breaks) 310 ± 81 149 ± 15 353 ± 49 356 ± 37 
Table 4.15 Respiratory quotient and locomotor activity in eight wild-type mice (C57b16) and 
PPARoi'" mice for 0-1 hour post-injection. 0-1 hour data were analysed comparing 
all treatments against vehicle, using one-way ANOVA with Dunnett's post-hoc test. 
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In figure 4. 
, 
there was a marginal reduction in food intake in the first 10 hours post- 
injection, with no significant hypophagia evoked by OEA at any individual time point, 
compared to vehicle, up to 24 hours post-injection. Fenofibrate displayed the same profile 
as OEA for the first 2 hours, but at the end of the dark phase (12 hours post-injection) 
food intake reduced to 58% of vehicle treated food intake (vehicle 2.95 ± 0.2; fenofibrate 
171 ± 0.4), and GW6471 treated food intake had reduced to 42% of vehicle treated (1.23 
± 0.2). Previous experiments have shown food intake to be higher duiring the dark phase 
than the light, yet in figure 4.26 fenofibrate administration appears to lead to similar 
levels of food consumption in both phases and GW6471 treated mice eat 57% more in the 
light phase than in the dark. In figure 4.27 with the PPARa 4- animals OEA, fenofibrate 
and GW6471 treated mice display a slight delayed onset of feeding. Analysis of these 
data suggests effects observed in figure 4.26 to be PPARci '" mediated. There was 
significant difference or trend observed in the knockout mice between treatments. 
Looking further at food intake in the wild type mice for the first 5 hours post injection we 
saw GW6471 to rapidly and significantly reduce food intake (P<0.001) for up to the 5 
hour point. Fenofibrate, to a lesser degree (P<0.01), evoked similar effects. In the 
ppARa'" mice, there was a delayed onset of feeding in the order of GW6471, fenofibrate 
and OEA, which was reversed after 4 hours. Mice treated with OEA failed to 
significantly reduce their food intake in the first hour in the wild type mice, yet in 
PPARa'- mice OEA administration significantly reduced food intake within the first 
hour. 
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Table 4.14 shows GW6471 treatment in wild type mice to significantly reduce activity in 
the first 24 hours and shows this effects to be reversed when administered to PPAR(x 1- 
mice, and in fact displays a trend towards stimulating locomotor activity as does 
fenofibrate in both wild type and PPARa 1" mice, albeit not significantly. We observe a 
depression of activity within the first hour with OEA, in wild-type mice and the same 
pattern in PPARc 4- mice. Activity in all PPARcc'" mice is lower than the wild-types. 
There was no significant effect of any treatment in oxygen consumption at 24 hours post- 
injection. GW6471 treated wild-type mice showed consistently lower oxygen 
consumption throughout the 24 hours compared to other treatments, albeit not significant, 
whereas this is not seen in PPARä e' mice. We see a familiar observation with OEA 
treated wild-type mice in the first hour post-injection, an acute transient reduction in 
V02. The same is seen in the PPARc '" mice. All changes in V02 caused by the different 
treatments become normalised and all treatments then follow the same profile. GW6471 
produces a significant reduction in respiratory quotient in wild-type mice 24 hours 
following injection (P<0.001), which is reversed compared to PPAR«'- mice at 24 hours. 
There is no significant change with any treatment in either wild-type or PPAR(x'" mice 
within the first hour post-injection. 
4.7.4 Discussion 
OEA produces no significant reduction in food intake at any individual time point over 
the first 24 hours. There is less of an effect with OEA administration (using the wild-type 
C57b16 mice) seen in this investigation than in previous experiments in this chapter. This 
variation has provided difficulty in determining how much of the OEA-evoked response, 
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previously recorded on food intake, is mediated by the PPARa receptor. It is unfortunate 
to have not obtained data similar to that observed before using OEA to compare to effects 
now seen using PPARa '- mice, it may be argued that we may be administering a less 
than optimum dose of OEA (or even that of GW6471). It is well known that cannabinoids 
and their endogenous ligands produce dose-response effects in a bell shaped curve, and 
that, unlike synthetic modulators, a maximal tolerated dose will not reflect the maximal 
effect of that endocannabinoid. In hindsight, maybe further investigation into the dose- 
response effects of OEA using a wider range of doses would have been useful to bring 
out its maximal regulatory effects on feeding behavior in vivo. In PPARct'" mice, OEA 
showed a significant (P<0.01) reduction in food intake in the first hour post-injection, 
suggesting that OEA is able to evoke transient satiety in mice without the presence of 
PPARa receptor. This suggests potentiation of OEA-evoked satiety mediated through an 
as yet unknown mechanism - previously suggested as an additive pathway. It has 
previously been reported that OEA's hypophagic effects are abolished in PPARa 
'' mice 
(Fu et al., 2003; Piomelli et al., 2006; Schwartz et al., 2008, Astarita et al., 2006) and 
there is no indication in the literature of an additive pathway, eventhough alternative 
receptors for OEA have been hypothesized to be involved in OEA's action on food intake 
(section 1.7). 
Throughout all feeding behaviour data, OEA alongside GW6471 and fenofibrate display 
delayed onset of feeding, lasting up to 4 hours in PPARa '- mice. As this is only observed 
with PPARa ligands this could be suggested to be ligand activity at a distinct target. 
These effects have not previously been seen in either wild-type mice, previous 
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experiments or the literature and are therefore possibly due to compensatory effects of the 
knockout animals following administration of its endogenous and synthetic ligands. 
Sedation resulting from OEA administration has not been documented in the literature 
and as a depression in activity with OEA was observed in both wild-type and PPARoi /- 
mice, it may be a mechanistic effect mediated through an unknown mechanism 
OEA again evoked a transient reduction in oxygen consumption, significantly sooner in 
PPARa '" mice and for up to 30 minutes in both PPARa '" and wild-type. This was 
reported previously in this chapter and was not seen with either of the other two ligands, 
implying this not to be a PPARa '- mediated effect. 
The rapid and long-lasting effects of GW6471 on food intake in wild-type mice has not 
previously been established, and its lack of effect in PPARa '" mice suggest GW6471 to 
be acting as a PPARa agonist with higher efficacy compared with fenofibrate. With 
knowledge of PPARa's ability to regulate food intake and as we also know what there is 
endogenous tone of endocannabinoids in our system to allow for low levels of chronic 
activation of receptors, it may be expected that the use of GW6471 may increase food 
intake in the animals, as this endogenous tone of OEA may lead to the naturally reduced 
levels of food intake via PPARa and this is a mechanism potentially disrupted following 
GW6471 administration, albeit we have determined some involvement of OEA via 
PPARa in the regulation of food intake, but we do not see any classical antagonism of 
this effect with GW6471 administration. As described in section 1.7.3 all PPARa ligands 
have different binding properties to the receptor which lead to differing effects in 
consequence. Due to our lack of knowledge on the binding properties of GW6471 at 
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PPARa receptor we can hypothesise whether this may be the case or not, but further 
investigation into binging properties and consequential effects of GW6471 at PPARa 
would allow for this. On closer inspection of the food intake 0-5 hours post-injection 
shows initial reduction in food intake to the same reduction between all treatments in the 
knockout mice, indicating a very likely similarity of effect between all treatments also. 
- 
We know OEA and fenofibrate do not cause malaise and GW6471 has previously shown 
to increase activity when administered alone, so the question lies whether all three 
compounds have similar affinities for and are acting at another receptor targets to cause 
this or are they causing a regulation of endogenous modulators of this effect. 
Fenofibrate has shown a similar profile to that of GW6471 in both wild-type and 
knockout mice. It has been more effective in inducing satiety than observed in previous 
experiments and OEA, using C57b16 mice, but the effects are less than GW6471. 
GW6471 significantly reduced activity in wild-type mice at 24 hours, which could be a 
result of GW6471 administration. Due to the lack of literature on the use of GW6471 in 
vivo, it is difficult to say if this is the case, but data from GW6471 in knockout mice 
suggest effects of GW6471 on activity to be PPARcL mediated. Activity levels over the 
24 hour period are lower in PPARa '" mice than wild-type, suggesting PPARa receptor 
mechanism pathway to contribute to activity. 
Our previous data suggest compounds to not affect locomotor activity levels, but it may 
be that PPARcL receptors may contribute to activity levels at times of de novo synthesis 
and activation of PPARa (for example, with endogenous OEA). 
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The trend of reduced V02 with GW6471 throughout the 24 hours post-injection in wild- 
type mice may further support the possibility of malaise evoked by this compound and 
the malaise may also be accountable for both a reduction in activity and food intake. This 
effect is not seen in the knockout animals suggesting it is PPARa mediated. 
Both GW6471 and fenofibrate show a transient reduction in V02, lasting up to 2 hours, 
which has been observed in previous experiments with fenofibrate, using C57b16 mice, 
and comparison with data from knockout mice suggest a PPARCt mediated pathway. A 
reduction in respiratory quotient is associated with increased oxygen consumption, but 
over the 24 hours we see GW6471 to have a trend towards the lowest oxygen 
consumption in wild-type mice, hence we would expect a an increase in respiratory 
quotient, in fact we see a highly significant decrease (P<0.001). This suggests a specific 
effect of GW6471 and the mechanism through which it exerts this effect is unknown. 
Decreased activity would influence the respiratory quotient more towards oxidation of 
carbohydrates (RQ=1) or higher, but results suggest increased fat oxidation relative to 
carbohydrates. We know PPARa transcriptional effects increase fat oxidation, yet 
changes in RQ toward fat oxidation (RQ=0.7) was not observed in previous experiments 
in this chapter in C57b16 mice at 24 hours post administration using GW6471 or 
fenofibrate, so unsure the mechanism by which this response is created remains obscure. 
Previous investigations suggested tonic PPARa activation, now with a lack of PPARot 
receptor the whole body may compensate by enhancing its own fat oxidation as a change 
to basal metabolic rates, which may explain the reduced RQ with all treatments including 
vehicle in the knockout animals, but does not explain similar RQ levels in the wild-types. 
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Overall, it has been difficult, with a reduced effect of OEA observed in the controls, to 
compare with the knockout animals to determine and further characterize the effects of 
OEA on satiety mediated through the PPARa receptor mechanism, but these results 
further profile the unknown effects of PPARa antagonist use in vivo. 
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4.8 Discussion 
This chapter provides good evidence of the use of effective doses of all OEA, fenofibrate 
and GW6471 in vivo. There were limitations in the interpretation of data from knockout 
animal models (section 4.7), where we did not see responses previously observed in 
wild-type mice, providing difficulty in the interpretation and comparison of effects to the 
PPARa '- mice. It may also be questioned if the results observed in the PPAR"'" group are 
true of such effects of this receptor knockout. The only reason they would not be is due to 
the development of unknown compensatory mechanisms during the study or incorrect 
genotyping of the animals as a result of human error, but we feel the latter not to be the 
case. It is not clear why the same sex, age and strain wild-type mice did not produce 
similar effects to all OEA, fenofibrate and GW6471 as previously observed, but as 
previously mentioned, this may be a dose selection fault, where the dose of OEA 
administered is not optimal to its regulating effects on food intake via PPARa. It would 
have been interesting to determine the expression levels of PPARa receptor in the gut in 
this group of animals compared to a previous set of mice used where we did see the 
regulatory effects on food intake. Lower levels of PPARa expression may well explain 
for the lack of effects observed, but as to what may have caused this to occur in such a 
subset group of mice only remains unclear. It is clear this experiment would be required 
to be repeated for a full understanding of the effects of each compound in this study. A 
better strategy would be to use mice in which PPARa gene disruption was under 
conditional influences, so that the gene is only disrupted as an adult, rather than from 
embryo. 
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OEA has clearly presented a hypophagic response in vivo yet its effects are seen to be 
rapid, yet transient. Identification of possible additive pathways on OEA's effects is very 
interesting and of some therapeutic use, as these transient effects of OEA could possibly 
be potentiated through other receptor mechanism, and made to last longer. Yet this would 
require further in vivo investigation. Isolation of each individual possible additive 
pathway involving OEA in this hypophagic response is required to identify whether 
pathways could be exploited to use OEA as an anorexiant agent. As it stands alone, it 
could not be used as an acute treatment to reduce feeding, but we have not investigated 
chronic in vivo effects of OEA, which may provide alternative advantages. 
Fenofibrate, as other drugs in the fibrate class, which are known PPARa agonists have 
been reported not to induce hypophagia at PPARa as potently as OEA, due to weaker 
binding affinities at the receptor, yet our data clearly show stronger effects of fenofibrate 
on the reduction of food intake compared to OEA. Further investigation would be 
required to determine how much of this effect is mediated by other mechanisms, which 
remain to be identified. GW6471 displayed the involvement of tonic PPARa receptor 
activation, adding to its regulation of hypophagic responses by OEA. It also showed clear 
effects on the reduction of food intake for up to the 24 hours measured 
- 
displaying a 
stronger profile as an anorectic agent compared to both OEA and fenofibrate. 
Now GW6471 has been successfully employed systemically in vivo, further studies will 
aim to provide additional information on its hypophagic responses and mechanisms. As 
yet, there is no effect of either compound individually or in unison to exploit as a clinical 
drug for the treatment of feeding disorders. Overall, therefore, the role of PPARa in 
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responses to fenofibrate and GW6471 is not clarified by the use of these knockout 
animals. 
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Chapter 5: GENERAL DISCUSSION 
5.1 FAAH and MAGL inhibition 
The use of FAAH inhibitors has potential over the use of synthetic CB receptor agonists, 
as FAAH inhibitors create actions, primarily, but not solely through CB 1 receptors. One 
interpretation of their lack of unwanted effects is that, by increasing the endogenous tone 
of CB1 receptor partial agonists, they evoke less of a tetrad response compared to 
synthetic full agonists. As a result of CB1 receptor activation, there will be the significant 
therapeutic effects of analgesia together with the potential for hypothermia, but without 
locomotor deficits, catatonia or any psychoactive CNS effects. In contrast, the selective 
MAGL inhibitor recently reported by Cravatt's group 
, 
JZL184 displayed the tetrad 
complete with unwanted CNS mediated psychotropic effects (Long et al., 2009). 
The use of naturally derived cannabinoids has led to the development of the drug Sativex, 
which is equiratios of CBD and THC. Its use in the treatment of spasticity in MS (Baker 
and Pryce, 2003) appears to be devoid of psychotropic effects, as it is found to `under 
perform' at CB, receptors. CB, receptor effects from its ligands are dose-dependant, 
therefore it is not entirely true that drugs acting at CB1 receptors are not useful due to the 
resulting CNS mediated effects, as this is avoided when applying specifically low doses. 
Whether synthetic drugs can be designed to have the same avoidance of CNS mediated 
effects at CB1 receptor is unknown, but clearly the application of purified cannabinoids or 
the modulation of eCBs and its system are highly favourable when targeting CB i 
receptors, for the treatment of various pathological states. 
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A full understanding of the eCB system is still ongoing, and many clinical implications of 
the use of naturally derived CB receptor partial agonists, namely the cannabinoids, as 
therapeutics exist. It has recently been reported that there is an up-regulation of CB2 
receptor expression in response to neuropathic pain and inflammation in 
neurodegenerative diseases, such as Huntington's disease and MS (Pertwee, 2008). Due 
to upregulation of such receptors, agonists at CB2 receptors unavoidably produce more 
effec. As CB2 receptor up-regulation is a direct result of the disease pathology, this 
provides a clear indication that they have an important role in the regulation of the 
disease, indicating a future potential target for inhibitors of eCB metabolism. 
With the presence of over 60 cannabinoid compounds found in the cannabis plant, we are 
provided with many differing effects of every compound still to investigate as potential 
therapeutics. The use of enzyme inhibitors can potentially be very beneficial, as FAAH 
and MAGL inhibitors act to increase the endogenous tone of eCBs or preserve 
exogenously administered cannabinoids to potentiate their effect and make it more long 
lasting by delaying its degradation (which we know to occur rapidly due to the de novo 
control of the eCB system). Such benefits could potentially be tissue specific if given 
orally, in our case, we would act to increase levels of eCBLs in the upper GI tract to 
induce satiety and at the same time avoid unwanted interaction with the CB receptors. 
FAAH inhibitors may prove a much better target compared to MAGL inhibitors, as 
FAAH is known to have many substrates, so inhibitors will cause an increase in many 
eCBs, whereas MAGL only has one main substrate, 2-AG. 2-AG is already present in the 
brain (Richardson et al., 2007) and in peripheral tissues as seen in chapter 4. Hence, 
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through inhibition of MAGL you would create an even higher level of 2-AG in certain 
tissues, which may produce a compensatory effect, causing stimulation of other 
hydrolysing enzymes to metabolise the overload or excess 2-AG. This provides a further 
problem of the inability to achieve therapeutically beneficial levels of 2-AG in vivo, 
especially in certain tissues. Because FAAH substrates also act at nuclear receptors, such 
as PPARs, transmitter-gated channels, such as TRPV 1, and GPCRS, including CB, 
GPR119 and possibly GPR55, the range of effects seen with FAAH inhibition could be 
enormous. The beneficial effects seen in vivo are likely to be a 
. 
summation of modest 
effects at each of these targets, in contrast to the `focused' effect of MAGL inhibition. 
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5.2 OEA and feeding behaviour 
Our results show OEA to cause hypophagic responses in mice, which supports findings in 
literature, where rats have been used to identify the effects of OEA on feeding behaviours 
(Fu et al., 2003). Findings in chapter 4 indicate a possible involvement of other receptor 
mediated responses and these are hypothesised to be GPR119 or TRPV1. The effects of 
OEA at these receptors is characterised using their respective animal knockout models 
(Wang et al., 2005) (Godlewski, 2009). Genetic tools are not ideal to isolate single 
mechanism pathways due to possible unknown compensatory effects. Alternatively, it 
would be better to determine OEA's effects on each mechanism using individual receptor 
antagonists 
- 
thus not disrupting the animals natural mechanisms in a chronic fashion. It 
would also be favourable to use dual administration of antagonists, where two or more 
receptors may potentially be involved in regulating one effect or response, to isolate a 
single pathway. Here, the physiological effects of the use of antagonists at their receptors 
would have to be accounted for. In our study, this proves to be difficult as there is no 
selective antagonist for GPR119 and no in vivo use of a TRPVI selective antagonist. 
Another way towards isolation of mechanism pathways is the use of tissue specific 
knockout models, this would aid further investigation of specific receptors in specific 
tissue locations, without causing systemic compensatory effects. 
Our results on the effects of OEA on food intake are confusing, as they indicate the 
involvement of unknown mechanisms, yet it has been determined that responses are a 
direct action of OEA and not a result of the `entourage effect'. This is now well 
supported in literature, with the growth of knowledge, since the hypothesis of the 
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entourage effect, of the individual roles of both AEA and OEA. It cannot be said the 
entourage effect does not play a role in other areas of investigation, but it is good to 
determine that effects of OEA on feeding behaviours is independent of that theory. 
A limitation in the investigation of OEA's effects in vivo is its rapid response and 
metabolism. There is no way of determining intracellular or extracellular levels so rapidly 
to determine whether OEA gets into cells to activate such receptors (for example the 
nuclear receptor PPARa). Even though our quantification method takes into account the 
whole tissue, we do expect that it does get into cells due to very large increases (30-fold) 
seen in tissues of the ileum and duodenum in chapter 4. 
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